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Differentiated cells are typified by their lineage restriction. Nevertheless, a pluripotent 
state of unrestricted multilineage differentiation potential may be experimentally 
endowed upon differentiated cells via the process of pluripotential reprogramming in 
which the lineage restriction of differentiated cells is undone. The resultant cells, 
known colloquially as induced pluripotent stem cells (iPSCs), become akin to 
pluripotent embryonic stem cells (ESCs) and pluripotent cells of the early embryo, 
thus gaining their characteristic developmental potential and other characteristics 
diagnostic of pluripotent cells. Conferral of pluripotency upon differentiated cells is 
achieved by overexpressing pluripotency-associated transcription factors in these 
cells, such as Oct4, Sox2, Klf4, and c-Myc. Here, I have investigated whether a 
heretofore underappreciated class of transcription factors, known as nuclear receptors, 
can function similarly to conventional pluripotency transcription factors to reprogram 
mouse fibroblasts into iPSCs. I have identified two nuclear receptors, Nrli2 and 
Nr5a2, that can enhance the efficiency of iPSC generation by about 3- to 4-fold, 
respectively. Saliently, Nr5a2 can fully replace the need for exogenous Oct4 to 
generate mouse iPSCs, making it the first known factor capable of “replacing” Oct4 in 
iPSC reprogramming. Its close family member Nr5a1 functions similarly in 
substituting for Oct4. Piqued by how Nr5a2 can replace the singularly important Oct4 
in iPSC generation, I have furthermore found that Nr5a2 is endogenously required for 
iPSC generation—bereft of it, few iPSCs form. Moreover, in reprogramming 
fibroblasts, Nr5a2 directly binds the Nanog enhancer and upregulates expression of 
the dominant pluripotency factor Nanog. In brief, my study illuminates an unexpected 
role for nuclear receptors in iPSC generation, identifies Nr5a2 as the first factor that 
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can functionally substitute for Oct4 in iPSC reprogramming (formerly thought 
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1.1 A plethora of cell types governed by transcriptional and epigenetic regulation 
The intricately complex mammalian body is composed of myriad cell types, each 
highly specialised to perform distinct cellular functions in specific tissues or organs. 
This wide spectrum of cell types in the body encompasses specialised cells such as the 
metabolic enzyme-laden hepatocytes in the liver, the impulse-firing neurons in the 
brain, and the mitochondria-enriched muscle cells within our musculature. In addition, 
distinct cell types assume unique morphologies designed to perform specialised 
functions. For instance, neurons possess lipid-based encapsulations, known as myelin 
sheaths that enshroud axons that permit the rapid propagation of impulses, whereas 
epithelial cells are cuboidal or columnar in shape so as to allow its tight packing in 
body cavity linings.  
These expansive distinctions between various cell types can in part be attributed to the 
unique compendium of messenger ribonucleic acids (mRNAs) which each cell 
possesses. Fundamentally, mRNAs are expressed transcripts from genes embedded in 
genomic deoxyribonucleic acid (DNA), which in turn encode the basic units of 
hereditary information within a cell.  This unique cocktail of mRNAs, also known as 
the transcriptome of a cell, is expressed in a process known as transcription, and 
transcription is largely modulated by highly specialised proteins known as 
transcription factors and epigenetic modulators. Transcription factors are DNA-
binding proteins that can recognise and bind to specific DNA consensus sequences 
and modulate gene expression. They commonly bind to the regulatory elements of 
genes such as their promoters, enhancers and even silencers in order to activate or 
repress the expression of these genes which they dock at. Upon binding of 
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transcription factors, the enzyme, RNA polymerase II may be recruited to promoter 
regions to transact gene transcription
1
. In addition, a host of other co-factors such 
activators and repressors may also be recruited to assist in the modulation of gene 
regulation. This transcriptional control is highly conserved from the simplest of model 
organism such as yeast to the highly complex of mammals such as us humans. 
Strikingly, the more complex the transcriptional regulation within a cell, the more 
complex is the organism
2
. Incidentally, transcription factors belong to the largest 
protein family in humans
3
.  
Transcriptional control per se is only one tier of cell fate regulation within a cell and 
other complex regulation is involved as well. For instance, epigenetics, which 
essentially refers to the mechanistic regulation (not in the context of transcription 
factors) of cellular phenotype regardless of the basic sequence information harboured 
by the genomic DNA, provides another mode of regulation within a cell. 
Interestingly, epigenetic factors may even be recruited by transcription factors to 
modulate cell fate. Delving more into the mechanisms behind transcriptional 
differences will reveal further that various epigenetic marks are in part responsible in 
bringing about these distinctions in genetic expression.  
One of the common epigenetic marks is DNA methylation, a process whereby a 
methyl group is incorporated onto a nucleotide, typically a cytosine that is usually 
found in cytosine-phosphate-guanine (CpG)-rich islands. A gene with a highly 
methylated promoter and enhancer would typically render it transcriptionally inactive, 
whereas unmethylated regulatory elements would commonly indicate that the genes 
are expressed. Specialised enzymes known as DNA methyltransferases are 
responsible for incorporating methylation marks on DNA. On the other hand, 
demethylases are responsible for removing these methylation marks. In addition to 
3 
 
DNA methylation, other epigenetic modulators such as histone modifications marks 
also play a role in regulating gene expression. For example, histone 3 lysine 4 
trimethylation (H3K4me3) marks are known to be found on active genes while 
histone 3 lysine 27 trimethylation (H3K27me3) and histone 3 lysine 9 trimethylation 
(H3K9me3) marks are typically found on the promoters of repressed genes
4,5
. 
Besides, DNA methylation and histone modifications per se, epigenetic changes can 
also be mediated by chromatin remodelling complexes such as that of Polycomb 
Repressive Complexes (PRCs), which primarily comprise Polycomb Group (PcG) 
proteins and are important in the context of development
6
. While the repressive 
complex of PRC2 is known to promote H3K27me3 marks to silence genes
7
, PRC1 
binds to repressive marks to induce conformational changes in chromatin
8,9
. The 
switch/sucrose non-fermentable (SWI/SNF) complex is another chromatin 
remodelling complex and notable constituents of this complex are the trithorax group 
(TrxG) proteins, which are H3K4 methytransferases
10
. 
All in all, both transcriptional and epigenetic regulation work in concert to modulate 
cell fate and hence bring about various differentiated cells within our body with each 
cell harbouring the same genetic material but are remarkably still able to assume 
distinct cellular functions and different morphologies. 
 
1.2 Embryonic stem cell, the common precursor cell 
Intriguingly, regardless of the dissimilarities of the myriad somatic cell types present 
in our body, these cells essentially originate from a common precursor cell within the 
early developing embryo. These versatile cells, known as embryonic stem cells 





and are characterised by their ability to divide indefinitely in culture as well as give 
rise to all cell types in the body. This intrinsic and unique ability to differentiate into 
various cell types originating from the three major germ layers, the primitive 
endoderm, the primitive ectoderm and the mesoderm, is known as pluripotency. This 
pluripotent hallmark of ESCs makes these cells ideal models to study development as 
we can investigate the myriad paths of cellular differentiation that ESCs embark on. 
In addition, as ESCs can be coerced into specific cell types under specialised cell 
culture conditions in vitro, they indeed hold great promise for regenerative medicine. 
As such, specific differentiated tissues derived from ESCs can be transplanted into 
patients to replace diseased tissues or perhaps organs. 
 
1.3 Important transcription factors governing the ESC fate: Oct4, Sox2 and 
Nanog  
As mouse ESCs are naïve cells that have yet to assume any developmental fate and 
are continuously self-replicating, they make excellent models to study transcriptional 
regulation of the pluripotent and self-renewing network as well as their directed 
differentiation. At the heart of the transcriptional network of ESCs is a trio of 
transcription factors, comprising Oct4, Sox2 and Nanog that serve as the important 
architects of ESC pluripotency and self-renewal.  
Oct4, a POU (Pit/Oct/Unc) homeodomain protein that is expressed from the Pou5f1 
gene, is highly expressed in the inner cell mass (ICM) of the mouse embryos as well 
as in ESCs. Besides its expression in ESCs, Oct4 is also highly expressed in epiblast 
stem cells (EpiSCs) and primordial germ cells (PGCs)
12
. The importance of this 
transcription factor is evidenced by the fact that the ablation of Oct4 results in 
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embryonic lethality at the peri-implantation stage of murine development
13
. 
Furthermore, the cells that do develop in the ICM are devoid of pluripotentiality and 
tend to differentiate towards a trophoblast fate
13
. Similarly, when the expression of 
Oct4 is reduced in ESCs, differentiation tends towards the trophectodermal lineage
14
. 
Strikingly, it is essential that the expression of Oct4 be kept at a fine-tuned and 
regulated fashion in undifferentiated ESCs as even a 1.5-fold increment of Oct4 




Sox2, which belongs to the Sox (SRY-related HMG box) family of proteins, 
possesses a DNA-binding domain known as the HMG (high mobility group) box. 
Sox2 is not only highly expressed in ESCs but also in other cell types such as neural 
progenitor cells
15
. Similar to the Pou5f1-null murine embryos, the knockout of Sox2 
results in peri-implantation lethality, albeit at a slightly later stage of development as 
compared to the Pou5f1-null ones
16
. Again, akin to Oct4 deficiency in ESCs, the 
repression of Sox2 expression inclines ESCs to differentiate towards the 
trophectodermal lineage
17
. On the other hand, the overexpression of Sox2 may result 
in the neural differentiation of ESCs
18
. Sox2 is also known to form a heterodimer with 
Oct4 and they synergistically regulate many important downstream target genes such 
as Nanog, undifferentiated embryonic cell transcription factor 1 (Utf1) and fibroblast 
growth factor 4 (Fgf4)
19-22
. 
Nanog, another homeodomain transcription factor that is highly expressed in ESCs, is 
also an important modulator in the maintenance of the ESC fate. Similar to Oct4, 
Nanog is highly expressed in PGCs
23
. Nanog was initially discovered from a screen of 
novel factors that can sustain mouse ESCs under leukemia inhibitory factor (LIF)-
deficient conditions
24
. The ability of Nanog in dispensing the requirement of LIF-
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Stat3 was also discovered by another independent group through a screen of factors 
identified from in silico differential display
25
. Nanog-null embryos fail to form a 
proper epiblast and cells within the ICM tend to differentiate into parietal 
endodermal-like cells
25
. In addition, cells devoid of Nanog tend towards 
extraembryonic endodermal differentiation, a phenotype akin to Pou5f1 knockdown
25
. 
However, unlike Oct4 and Sox2, Nanog dimerises with itself and this homodimer 
interacts with other ESC-relevant factors to sustain ESC pluripotency
26
. In addition, 
unlike Oct4 and Sox2, subpopulations of ESCs do not express Nanog. However, ESC 
subpopulations devoid of Nanog tend to differentiate towards the primitive 
endodermal lineage
27
. Nonetheless, Nanog is an important transcription factor in 




Definitely, the transcription factors, Oct4, Sox2 and Nanog are not the only important 
pluripotent mediators in ESCs. There are also other transcription factors such as Sall4, 




1.4 The first derivations of mouse and human ESCs 
ESCs were first isolated by Martin Evans, Matthew Kaufman and Gail Martin from 
mouse embryo back in 1981
33,34
. It was only very much later in 1994 that human 
ESCs were harvested from human blastocysts by Ariff Bongso and co-workers
35
. 
However, they were unable to maintain the harvested human ESCs for long term in 
culture and were hence unable to derive a stable cell line. Unlike Bongso et al,  Jamie 
Thomson and co-workers went on to successfully derive and patent five independent 
human ESC lines in 1998
36
. These successful derivations of multiple human ESC 
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lines have not only opened the gateway for the study of the intrinsic pluripotent and 
self-renewing capabilities of human ESCs but have also allowed scientists to mirror 
the in vivo development of the human body through in vitro-mediated differentiation. 
 
1.5 The issues that plague the utilisation of human ESCs for regenerative 
medicine 
Although human ESCs are largely derived from excess embryos obtained from 
fertility clinics, their utilisation faces considerable backlash from pro-life groups 
which advocate that it is unethical to destroy embryos as they believe that human life 
begins upon conception. This ethical issue has led to the impeding of the smooth 
implementation of human ESCs in disease treatment. Moreover, as human ESC lines 
are unable to be utilised for patient-specific treatment, their potential transplantation 
into diseased individuals may elicit an undesirable immune response. Even if 
transplantation is performed, the consumption of immunosuppressive drugs may be 
necessary to prevent tissue rejection complications. Nonetheless, in spite of these 
drawbacks, several clinical trials utilising differentiated tissues derived from human 
ESCs are currently underway. Thus, gradually, the usage of human ESCs to treat 
diseases might become an actuality in the near future.  
Concomitant with the ethical and tissue rejection concerns that used to plague the 
usage of human ESCs, scientists were also pro-actively searching for alternative 
techniques to overcome these perennial issues. The two revolutionary ideals scientists 
wanted to achieve were to completely avoid the utilisation of human ESCs as well as 
to achieve patient-specificity for potential cell-based regenerative therapy.  
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1.6 Differentiation was previously conceived as an irreversible process 
Decades ago, it was thought that the differentiation of cells is not only a unidirectional 
process but also an irreversible one. The common notion then was that when either the 
pluripotency of an ESC or the multipotency of a precursor cell is lost, it would never 
be reacquired.  
The developmental potential of a cell can be appropriately represented by a marble 
rolling down an epigenetic landscape (Figure 1), a concept first coined by the 
developmental biologist Conrad Waddington
37
. At the top of this epigenetic landscape 
is a totipotent cell (purple marble). This totipotent cell exhibits global demethylation 
on its genomic DNA. However, as the marble rolls down to the next lower level of the 
epigenetic landscape it acquires epigenetic marks such as repression of differentiation 
genes and hence loses its developmental potential to become a pluripotent cells (blue 
marble). As the marble moves lower down the landscape, it further loses its 
pluripotent nature and becomes multipotent (red marble). At this stage it acquires 
more epigenetic marks such as promoter hypermethylation and X-chromosome 
inactivation. More epigenetic marks are acquired until it reaches the bottom of the 
landscape in which it becomes a unipotent cell (green marble). For instance, if a 
unipotent cell were to be converted back to a pluripotent cell, it has to first lose all its 
entrenched epigenetic marks and this process is seemingly impossible (which requires 




Development, 2009, 136(4): 509-23 
Figure 1. The developmental potential of a cell as depicted by an epigenetic 
landscape. The purple marble represents a totipotent cell. As the cell loses more and 
more of its developmental potential, it is represented lower down the landscape. The 
blue marble represents a pluripotent cell, the red marbles represent multipotent cells 
whereas the green marbles represent unipotent cells.  
 
However, this erroneous notion of differentiation being a unidirectional process is 
now debunked and de-differentiation, also known as reprogramming of somatic cells 
is actually possible as convincingly evidenced by the employment of various 
reprogramming methodologies (Figure 2).            















                                               Cell Stem Cell, 2007, 1(1): 39-49 
Figure 2. Different methodologies to reprogram. Somatic cells can be 
reprogrammed into pluripotent cells by four primary methods: nuclear transfer, cell 
fusion, explantation in cell culture, and by the introduction of defined factors.  
 
1.7.1 Cell fusion 
Cell fusion is a process whereby a cell fuses with another cell to form a hybrid cell 
(Figure 2). Interestingly, this process occurs spontaneously in the body during the 
differentiation of cells in the muscle and bones.  Besides natural cell fusion that 
occurs in vivo, different cells can also be induced to fuse with one another in vitro. 
For instance, when a somatic cell fuses with a pluripotent cell such as an ESC, the 
resultant hybrid cell still remains pluripotent and exhibits characteristics very similar 
to its parental pluripotent cell. This method of cell fusion is one of the ways in which 
a somatic nucleus can be reprogrammed to a state of pluripotency. Reprogramming 
essentially occurs because of the critical transfer of the complete complement of 
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nuclear regulators within the pluripotent cell to the somatic cell. De-differentiation of 
fibroblasts and myeloid precursors after their fusion with human ESCs are classic 
examples of successful reprogramming with this cell fusion technique
38,39
. However, 
the major drawback of this reprogramming methodology is that it yields tetraploid 
cells which possess twice as much genetic material than they should typically have, 
and thus the progeny of these cells are not therapeutically viable.  
 
1.7.2 Somatic cell nuclear transfer 
Somatic cell nuclear transfer (SCNT) entails the insertion of a nucleus belonging to a 
somatic cell into an enucleated egg (Figure 2). The somatic nucleus will consequently 
be reprogrammed by components within the cytoplasm of the egg cell and shock is 
then applied to stimulate the cell to divide. Interestingly, this process of 
reprogramming recreates zygotic genome activation that occurs after the fertilisation 
of an oocyte with a sperm, and entails the erasure of silencing marks to activate the 
expression of zygotic genes. After several rounds of cellular division, a blastocyst is 
formed, which can in turn go on to develop into an adult animal. Dolly, the sheep, 
which was the first mammal to be cloned, is one successful example of SCNT put into 
practice
40
. Subsequently, other animals such as dogs were also successfully cloned via 
this technique of reprogramming
41
. However, utilising SCNT on animals is as far as 
this technique can get with respect to the creation of organisms. When translating 
SCNT to human cloning, serious ethical issues are brought forth. For instance, 
application of SCNT to create modified human blastocysts may allow us to implement 
it for human reproductive cloning, which can in turn bring about certain serious 
societal issues. Furthermore, the obtaining of oocytes from human patients raises 
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concerns whether biological material had been properly obtained from consenting 
individuals. Besides reproductive cloning, SCNT can also be beneficially utilised to 
create patient-specific ESCs (whereby ESCs are derived from the cloned blastocysts) 
which can be differentiated into various differentiated cell types that can be used for 
therapeutic purposes. However, likewise, perennial ethical concerns provide an 
impediment to its utilisation in the clinic. Ethical issues aside, the technique of SCNT 
per se is highly inefficient a process thus requiring several oocytes to be utilised 
before a successfully reprogrammed cell is obtained.  
 
1.7.3 Cell explantation 
Cell explantation is a technique whereby immortalised cells are selected for from a 
culture of somatic cells (Figure 2). These immortalised cells which are selected for 
could possess multipotent or pluripotent characteristics. Amongst all the 
methodologies employed to reprogram, cell explantation is the least commonly-
utilised technique. This method of reprogramming has been more commonly and 
successfully demonstrated in the derivation of spermatogonial stem cells from 
neonatal and postnatal animals. This is exemplified in the long term culturing of 
PGCs in specialised culture which will eventually give rise to embryonic germ (EG) 
cells that are pluripotent
42
. This technique is common in germ cells because they 
possess pluripotential characteristics. In another instance, pluripotent cells can also be 
derived from germline stem cells harvested from neonate mouse testes
43
 as well as 
adult testes
44
. Interestingly, parthenogenesis of an unfertilised egg is also another 
means in which pluripotent cells can be derived. Parthenogenesis occurs in certain 
female organisms and involves the asexual reproduction of an embryo, without any 
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fertilisation from a male counterpart. Parthenogenetic ESCs have so far been 
successfully derived from mice and monkeys
45,46
. However, the other major shortfall 





1.7.4 Reprogramming with transcription factors 
In a groundbreaking study back in 2006, Kazutoshi Takahashi and Shinya Yamanaka 
demonstrated that somatic cells can be converted into cells that resembled ESCs with 
the simple retroviral transduction of mouse fibroblasts with four transcription factors 
(Figure 2 and 3): Oct4, Sox2, Klf4, and c-Myc (OSKM)
48
. These converted cells, 
which share morphological and pluripotent characteristics with ESCs, are known as 
induced pluripotent stem cells (iPSCs). Shortly after the discovery of the ability to 
reprogram murine somatic cells, the generation of human iPSCs with these same four 
transcription factors was also successfully demonstrated
49,50
. OSKM was however not 
the only reprogramming cocktail reported and other transcription factors such as 
Nanog have also been used to reprogram
51
. As reprogramming with transcription 
factors is a highly inefficient process as compared to other methods such as cell fusion 
and SCNT, OSKM is most likely an incomplete representation of factors needed to 
orchestrate efficient and rapid reprogramming. Hence, the search for other factors that 
could enhance or play a role in reprogramming is pivotal and warranted. Nonetheless, 
the reproducibility of reprogramming with these four transcription factors have been 
universally exemplified by the successful generation of iPSCs from various species as 







Figure 3. Reprogramming of somatic cells with transcription factors. Somatic 
cells such as skin fibroblasts can be converted to cells that highly resemble ESCs by 
the introduction of four transcription factors: Oct4, Sox2, Klf4 and c-Myc. These 
converted cells are known as iPSCs. 
 
1.8. The canonical reprogramming factors 
1.8.1 Oct4 in reprogramming 
Besides the reprogramming formulation reported by Kazutoshi Takahashi and Shinya 
Yamanaka, both Oct4 and Sox2 were also part of the reprogramming cocktail (OCT4, 
SOX2, NANOG and LIN28) discovered by Jamie Thomson’s group51. The initial 
discovery that Oct4 could induce reprogramming did not come as a surprise as a 
wealth of information had been previously accumulated on the role of Oct4 in the 
maintenance of ESC pluripotency
53,54
. Amongst the four canonical reprogramming 
factor, Oct4 is by far the most important as evidenced by the dispensability of the 
other reprogramming factors either by other factors or by chemical complements
52
. 
Prior to the findings reported in the study herein, no other factor has been reported to 
be able to directly substitute for Oct4 in reprogramming. Even close family members 





. It is not surprising that Oct4 is difficult to be replaced in 





1.8.2 Sox2 in reprogramming 
The importance of Sox2 in ESCs is somewhat synonymous with that of Oct4 in 
ESCs
20-22
. Hence, it was no surprise that both Sox2 and Oct4 were consistently 
reported to be potent reprogramming factors in different iPSC-generating 
combinations
48,51
. However, unlike Oct4, Sox2 does not hold such critical importance 
in reprogramming as compared to its counterpart. First, Sox2 is dispensable for 
reprogramming in cells such as neural progenitor cells that express high levels of 
endogenous Sox2
56
. Even close SRY-related family members of Sox2 such as Sox1 
and Sox3 are able to replace the former in reprogramming
55
. Sox2 can even be 
replaced by chemical compounds such as inhibitors of the transforming growth factor-
β (Tgf-β) pathway57.  Nonetheless, Sox2 remains to be an important pioneering 
reprogramming factor and many studies still include it into their reprogramming 
cocktail to generate iPSCs.  
 
1.8.3 Klf4 in reprogramming 
Klf4 is a krüppel-like transcription factor and hence it possesses three typical zinc 
finger motifs at its C-terminus. When the reprogramming quartet was discovered by 
Kazutoshi Takahashi and Shinya Yamanaka
48
, Klf4 came as a surprise to many, as 
Klf4 (and its family members) have not been implicated in maintaining the 
pluripotency or self-renewal of ESCs. Strikingly, our group subsequently reported that 
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Klf4 and its close family members, Klf2 and Klf5 are important for the self-renewal 
of mouse ESCs
58
. Although single knockdowns of each of the Klf factor did not yield 
a phenotype in mouse ESCs, a combined knockdown of all three Klf factors (Klf2, 
Klf4 and Klf5) resulted in an overt differentiation of the ESCs. Surprisingly, another 
group reported the importance of Klf5 in mediating the self-renewal of mouse 
ESCs.
59,60
 They reported that the ablation of Klf5 prevented the successful derivation 
of mouse ESCs from the ICM, and on the other hand, the overexpression of Klf5 in 
mouse ESCs suppressed differentiation in the absence of LIF
60
. More interestingly, 
Smith and colleagues showed that the Oct4 and Stat3 pathways converge on the Klf 
transcriptional circuitry (Klf2 and Klf4, respectively) to uphold the pluripotency and 
self-renewal framework in mouse ESCs
61
. More relevantly, the importance of the 
close family members of Klf4 in ESC biology was shown in the context of 
reprogramming with the successful replacement of Klf4 with  Klf2, Klf5 and even 
Klf1
55
. In addition, chemical replacements of Klf4 have been discovered
62
. As the 
discovery of Klf4, a known oncogenic factor
63
, as a reprogramming factor had 
initially caused concerns in the scientific community, its replacement therefore proves 
to be beneficial for the advancement of the iPSC field.  
 
1.8.4 c-Myc in reprogramming 
c-Myc a proto-oncogenic factor, has been implicated in the maintenance of mouse 
ESC pluripotency and self-renewal
64
. In addition, c-Myc plays a role in dictating 
global chromatin architecture
65
. The use of c-Myc to generate iPSCs was a major 
concern as c-Myc is a highly oncogenic factor and hence its utilisation poses a safety 
issue. Fortuitously, it was shown that c-Myc is dispensable for reprogramming
55,66
. 
Nonetheless, the omission of c-Myc in the cocktail of reprogramming factors results 
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in a marked reduction of efficiency in the generation of iPSCs
55,66
. Strikingly, N-Myc 
and L-Myc, close family members of c-Myc can replace the canonical reprogramming 
factor in reprogramming
55
. Intriguingly, Kathrin Plath and colleagues demonstrated 
that amongst the members of the reprogramming quartet, c-Myc is the factor which 
induces the most ESC-like transcriptional expression
67
. In addition, they also showed 
that c-Myc is pivotal in orchestrating the initial stages of reprogramming.  The major 
drawback of using c-Myc to reprogram is that it results in a high incidence of tumour 
formation in the derived chimaeric mice
68
. However, if non-tumorigenic L-Myc or c-
Myc mutants (W136E and dN2) are used in place of wildtype (WT) c-Myc, the 
tumour formation incidence is not only markedly curtailed, but the efficiency of 




1.9 Advantages of iPSCs 
The ground-breaking discovery of reverting somatic cells to a state of pluripotency 
with transcription factors by Kazutoshi Takahashi and Shinya Yamanaka was indeed a 
boon to the scientific community as well as to regenerative medicine. Patient-specific 
iPSCs could be easily generated and differentiated into relevant cell types for 
treatment of diseases. This use of patient-specific cells and tissue will effectively 
bypass the issue of tissue rejection which would otherwise be a problem if human 
ESC derivatives are to be used instead. However, a recent finding reported that 
aberrant gene expression in the differentiated cells derived from iPSCs can in fact 
give rise to immunogenic reactions when transplanted into recipients
69
. Hence, proper 
evaluation has to be performed on iPSCs that may be used for potential clinical 
application and further optimisation of the derivation of higher quality iPSCs needs to 
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be achieved. Nonetheless, besides potentially being able to overcome tissue rejection 
issues, the utilisation of iPSCs will sidestep the perennial ethical red tape that is 
associated with human ESCs. The therapeutic capacity of iPSC was first shown in the 
treatment of sickle cell anaemia in a mouse model
70
. Since this proof of principle 
experiment in mice, various human iPSCs from many different diseased patients have 
been successfully derived. Some of the diseases that have already been modelled 
include amyotrophic lateral sclerosis, Leopard syndrome, and Hutchinson Gilford 
Progeria syndrome
71-74
. Being able to generate patient-specific iPSCs from diseased 
individuals and then differentiating them into healthy tissue to treat these patients is 
indeed a potentially huge step forward for regenerative medicine. 
 
1.10 The biology of reprogramming to iPSCs 
Reprogramming with transcription factors fundamentally entails a gradual 
reacquisition of epigenetic marks prevalent in ESCs (Figure 4) and hence a 
concomittant adoption of a transcriptome that is ESC-like.  
Besides re-establishing a demethylated profile on CpG islands at ESC-relevant gene 
regulatory regions, differentiated genes have to be methylated and hence become 
repressed. In addition, to the reacquisition of ESC-like methylation profiles, 
appropriate histone modifications have to be adopted as well. Interestingly, ESCs are 
known to have genes which exhibit both the activating histone modification of 
H3K4me3 and repressive histone modification of H3K27me3
4
. These occurrences of 
both histone marks on a single gene are commonly known as bivalent domains
4
.  
However, when ESCs differentiate and acquire a particular lineage fate, these 
bivalent-marked genes are resolved to display either histone modification and thus 
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become either activated or repressed. For instance, when fibroblasts are first 
introduced with the OSKM retroviruses, they initially possess repressive H3K9me3 
histone marks on pluripotency-associated genes such as Pou5f1 and Nanog
75
. In 
addition, the promoter regions of the Pou5f1 and Nanog genes would be highly 
methylated, indicative of their silenced state.  
Prior to attaining a terminally and fully pluripotent stage, differentiated cells 
undergoing reprogramming transit through an intermediate “partially-reprogrammed” 
stage; these intermediates are known as partially-reprogrammed iPSCs or “pre-
iPSCs”. Though generally present only transiently in reprogramming cultures, pre-
iPSCs may be captured and stably maintained in a partially-reprogrammed state; it is 
also noteworthy that pre-iPSC does not refer to a single obligate waypoint on the path 
to full reprogramming, but rather there is an entire collection of distinct pre-iPSC 
intermediate states, each of which is either closer or farther away from a fully-
reprogrammed state. These pre-iPSCs may have a small extent of demethylation 
occurring at the promoters of the Pou5f1 and Nanog genes and have several repressive 
H3K9me3 marks replaced by the activating H3K4me3 marks. Furthermore, genome-
integrated retroviruses are at this point still generally unsilenced and are actively 
expressing their transgenes. Interestingly, a cocktail of GSK3 and MEK chemical 
inhibitors collectively known as 2i or the DNA methyltransferase inhibitor, 5-aza-
cytidine, alone can coerce pre-iPSCs to become fully-formed iPSCs
76,77
. During 
reprogramming, cells undergo a mechanistic cellular change known as mesenchymal 
to epithelial transition (MET) before finally becoming a fully-formed iPSCs 
(assuming that the starting cells are fibroblastic)
78,79
. Hence, partially-reprogrammed 
cells may adopt an epithelial morphology at the intermediate stage of reprogramming. 
Downregulation of fibroblast surface antigen, Thy1 and the upreglation of the ESC-
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specific cell surface marker, stage-specific embryonic antigen -1 (SSEA1) occur at the 
early stages of reprogramming
80
.  
At the final stage of reprogramming, mouse iPSCs would have already completely 
lost its fibroblastic morphology (if fibroblasts were the cells that were reprogrammed) 
and have also adopted a dome-shaped and three-dimensional morphology very much 
akin to mouse ESCs (Figure 4A). When cells are fully reprogrammed, the promoter 
regions of Pou5f1 and Nanog are totally demethylated, and most if not all of the 
repressive H3K9me3 marks have been substituted for activating H3K4me3 marks 
(Figure 4B). In addition, all retroviruses should have been ideally silenced, and 
endogenous genes such as Pou5f1, Sox2 and Nanog should be sustaining the newly-
established pluripotent framework in the iPSCs (Figure 4C). De novo DNA 
methyltransferases Dnmt3a and Dnmt3b are induced to methylate and silence the 
retrovirally-transduced transgenes. The final stage of reprogramming is also marked 
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Figure 4.  Stages of reprogramming to mouse iPSCs. (A) Morphological changes 
during reprogramming from a stretched, flattened morphology to an epithelial one 
and finally to a dome-shaped morphology, similar to mouse ESCs. (B) Histone 
modification changes during reprogramming. Repressive histone mark, H3K9me3 is 
gradually lost on the promoters of pluripotency-associated genes such as Pou5f1, Sox2 
and Nanog, and are completely replaced by activating H3K4me3 marks. (C) 
Transduced retroviruses express transgenes, and are eventually silenced by de novo 
methyltransferases. Endogenous pluripotent genes, Pou5f1, Sox2, and Nanog 
subsequently sustain the pluripotent framework. 
 
1.11 The rapid development of the field of iPSC 
After mouse fibroblasts were first successfully reprogrammed into iPSCs in 2006, 
many stem cell scientists around the world joined in the iPSC arena as they saw the 
great potential of these ideal patient-specific pluripotent cells that could render the 
utilisation of human ESCs dispensable. This great interest in the field of iPSCs led to 
the rapid development of induced pluripotency by factor introduction, and a great 
wealth of information with respect to iPSCs has been accumulated thus far. 
In a salient study, Kazutoshi Takahashi and Shinya Yamanaka first reported in 2006 
that they had reprogrammed mouse fibroblasts into iPSCs, selecting for successfully-
reprogrammed iPSCs by virtue of activation of a Fbx15-NeoR reporter transgene—
Fbx15 is a gene highly expressed in ESCs and iPSCs
48
. However, the iPSCs derived 
in that pioneering study were not quite akin to mouse ESCs as the Pou5f1 promoter 
was still highly methylated, gene expression was not totally similar to mouse ESCs, 
and live-born chimaeric mice could not be successfully generated following blastocyst 
complementation with these iPSCs. As a result of these significant dissimilarities to 
ESCs, many questions were thus raised on whether iPSCs generated with the 
introduction of transcription factors was a good reprogramming technique.  
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The Fbx15 gene, although very highly expressed in mouse ESCs, but dispensable for 
sustaining pluripotency, was in fact not an ideal marker to select for good quality 
iPSCs. Shinya Yamanaka and colleagues then utilised transgenic cells that harbour the 
GFP reporter driven by the Nanog promoter and enhancer to select for better quality 
iPSCs
81
. Remarkably, these Nanog-GFP-positive iPSCs not only possessed a global 
transcriptome more similar to mouse ESCs, and largely displayed demethylated Oct4 
promoter profiles but more importantly were able to give rise to live-born chimaeras. 
Furthermore, these iPSCs were also shown to be capable of germline transmissibility.  
Similarly, Rudolf Jaenisch and colleagues utilised transgenic cells harbouring the 
GFP reporter driven by the endogenous Pou5f1 regulatory elements to select for more 
bona fide iPSC clones
82
. Remarkably, they were not only able to recapitulate the 
improved findings by Shinya Yamanaka and colleagues, they were also able to derive 
late-stage embryos after injection into tetraploid mouse blastocysts. Tetraploid 
complementation which entails the injection of cells into tetraploid embryo (by fusing 
two embryos together)  to see if these cells are capable of giving rise to an entire live-
born mouse is the most stringent of pluripotency assays. Although Rudolf Jaenisch 
and colleagues may have failed to derive a live-born mouse directly from their 
tetraploid complementation assays, the derivation of live embryos were nonetheless a 
big stepping stone to the improved methodology of iPSC generation. Nevertheless, 
many groups have faithfully adopted this benchmark of selecting more bona fide iPSC 
clones with the Pou5f1-GFP promoter for their reprogramming studies
83-87
. 
Subsequently, in 2009, independent groups were able to show that viable mice can be 







1.12. Various cell types from various species reprogrammed 
Fibroblasts which are mesoderm-derived were the first cell types that were 
reprogrammed to iPSCs
48
. Subsequently, B lymphocytes which were also mesodermal 
in origin were shown to be amenable to reprogramming
91
. However, their 
reprogramming required the additional specific knockdown of the B lymphocyte-
specific transcription factor, Pax5 and the overexpression of C/EBPα in addition to 
OSKM. Remarkably, Eminli et al subsequently showed that B lymphocytes could be 
reprogrammed with only OSKM
56
. Tellingly, mesodermal cells were not the only 
cells that were inclined to reprogramming. iPSCs were also generated from 
endodermal cells such as those in the stomach and liver
92
. Ectodermal cells such as 
keratinocytes and neural progenitor cells were also demonstrated to be 
reprogrammable
93-96
. Remarkably, OSKM can also reprogram cells from non-obese 
diabetic (NOD) mice, in which the derivation of ESCs was previously considered to 
be non-permissive
97
. However, the constitutive expression of Klf4 and c-Myc is still 
required in these NOD mice derived-iPSCs. 
The universality of OSKM in reprogramming was not only demonstrated on various 
tissue types but also various species. Human iPSCs were derived
49,51,98
 not long after 
the demonstration of the generation of mouse iPSCs
48
. Several groups were also able 
to generate rat iPSCs in the presence of LIF with or without certain cocktails of 
chemical inhibitors
99
. While Li et al used chemical inhibitors to GSK3, MEK, TGF-β 
in the presence of LIF
99,100
, Liao et al used LIF alone without any chemical 
inhibition
100
. Since then iPSCs have been successfully derived from various other 




 and even the rabbit
105
. The repertoire of 
various cell types and various species that could be reprogrammed into iPSCs is still 
increasing. Nonetheless, despite this increasing repertoire, it should be noted that the 
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ultimate goal for iPSC is its eventual realisation in regenerative therapy for man and 
hence more focus should be put into the optimisation of the efficiency and safety of 
iPSCs. 
 
1.13. Various techniques to generate iPSCs 
iPSCs were first generated with the retroviral transduction of transcription factors
48
. 
After which, lentiviruses were also utilised to overexpress reprogramming factors in 
the generation of iPSCs
36,106
. Usage of both retroviruses and lentiviruses not only 
poses a safety issue but also tends to generate poor quality iPSCs if they are not 
silenced after integrating into the host cell genome. Aberrant integration into the host 
genomic DNA may also result in the undesirable silencing, activation or disruption of 
certain genes. Furthermore, unlike retroviruses, lentiviruses tend to be constitutively-
expressed and are considerably difficult to be silenced.  Notably, several groups 
utilised drug-inducible lentiviruses to generate iPSCs so as to control the expression 
of the otherwise difficult-to-silence transgenes
80,106
. Stadtfeld et al first overcame the 
issue of genomic DNA perturbation by successfully reprogramming cells with 
adenoviruses that do not integrate into DNA
107
. However, despite the addressing of 
the genomic DNA integration issue, a non-viral approach to reprogramming was still 
desired.  
Shinya Yamanaka and colleagues appropriately addressed this concern by 
reprogramming cells with the simple transfection of plasmids
108
. They successfully 
generated mouse iPSCs by repeated transfection of MEFs with a single plasmid vector 
harbouring the Pou5f1, Sox2 and Klf4 transgene in addition to another plasmid 
harbouring only the c-Myc transgene. The authors also showed that the repeated 
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plasmid transfections did not result in their integration into the genomic DNA. 
However, the efficiency of reprogramming with plasmid transfection is extremely low 
even when compared to retroviral delivery. Nonetheless, other groups were able to 
perform plasmid transfections with a much greater reprogramming efficiency, albeit 
with a totally different vector design. For instance, instead of separately expressing 
transgenes from different expression vectors, all transgenes can be combined into one 
single expression vector in the polycistronic vector with a pCAG backbone
109
. The 
piggyBac vector is another such plasmid that can harbour all transgenes and can 
reprogram cells with high efficiency without genomic integration or introducing any 
viral elements
110-112
. Upon transfection of the piggyBac constructs, transposase which 
is expressed from a helper plasmid transfers the reprogramming transgenes harboured 
by the piggyBac vector into the genomic DNA of target cells in a process known as 
transposition. After reprogramming takes place, integrated transgenes can be removed 
either by Cre-mediated excision
111
 or transposase-mediated excision into an empty 
helper plasmid
110
. Capitalising further on the discoveries of reprogramming with 
plasmid transfection, Jia et al utilised a minicircle vector to generate iPSCs
113
. 
Besides not integrating into the genome, the other advantages of this minicircle vector 
are that transfection efficiencies are high and the vector is purely a eukaryotic 
expression cassette that does not contain any bacterial origin of replication as well as 
any antibiotic resistance genes. In addition, the vector conveniently harbours all four 
canonical transcription factors in its design.  
In a radical attempt to move away from retroviral or plasmid delivery, two groups 
were able to successfully generate iPSCs with the direct introduction of recombinant 
proteins
114,115
. However, akin to reprogramming with plasmid transfection, the 
efficiency is extremely low as compared to viral delivery and repeated direct delivery 
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of recombinant proteins is required. Moreover, recombinant proteins are tedious to 
generate and they degrade very rapidly as well. Interestingly, Derrick Rossi and 
colleagues devised a method to reprogram human cells with the simple introduction of 
synthetically modified mRNAs
116
. Since RNAs are highly degradable molecules, the 
authors attached a 5’ guanine cap to the mRNAs to boost their half-life. Another 
concern of using mRNAs to reprogram is that the introduction of RNAs into cells has 
been shown to elicit an innate response from the host
117
. The authors addressed this 
issue by designing the mRNAs with a phosphatase, as 5’ triphosphates have been 
shown to trigger an immunogenic reaction
118
. Strikingly, Derrick Rossi and 
colleagues also demonstrated the ability to mediate direct differentiation with these 
synthetically modified mRNAs by successfully differentiating their derived iPSCs 
into myotubes with the introduction of the MYOD mRNA.  This method of 
reprogramming (and directed differentiation) with modified mRNAs holds great 
potential for its future utilisation in regenerative medicine. Nonetheless, more 
optimisation is still required to avoid repeated transfection and to further augment its 
efficiency in reprogramming. 
 
1.14. Screen for reprogramming factors 
1.14.1 Initial screen for factors that could reprogram 
In 2006, Kazutoshi Takahashi and Shinya Yamanaka screened a list of 24 
transcription factors (Table 1) in search for factors that could reprogram mouse 
fibroblasts to a pluripotent state
48
. These factors were selected for the screen based on 
their proposed roles in sustaining the ESC identity. Interestingly, some of these 
factors were not WT ones but were in fact mutant counterparts. For instance, Grb2 per 
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se has detrimental effects on pluripotency
119,120
, and hence Grb2ΔSH2, a dominant-
negative mutant
121
, was instead utilised in the screen. In addition, T58A-c-Myc, Stat3-







 respectively, were also used in the screen.  
 
Table 1. List of 24 transcription factors screened by Takahashi and Yamanaka 
for reprogramming
48



























The Japanese researchers used fibroblasts derived from transgenic mice harbouring 
the β-galactosidase and neomycin resistance genes targeted via homologous 
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recombination to the Fbx15 gene
125
.  Fbx15 is a gene that is highly expressed in ESCs 
but is dispensable for the maintenance of their pluripotency. Hence, ESCs harbouring 
the neomycin resistance genes are highly resistant to G418 treatment, unlike somatic 
cells, which are sensitive to even low doses of G418. The screen for factors that could 
reprogram first embarked with the individual transduction of mouse fibroblasts with 
each of the 24 factor in search for G418-resistant colonies. This initial screen however 
did not yield any G418-resistant colonies. On the other hand, when mouse fibroblasts 
were concomitantly transduced with all 24 factors, G418-resistant colonies that 
resembled mouse ESCs with respect to their morphology were obtained. Despite these 
cells expressing ESC-relevant genes, and exhibiting promoter demethylation of the 
Nanog and Fbx15 loci, the Pou5f1 loci of these colonies were still largely methylated. 
Nonetheless, Kazutoshi Takahashi and Shinya Yamanaka decided to narrow down on 
a smaller pool of factors amongst the 24 candidate factors that were critical in the 
formation of the ESC-like colonies. They removed one factor at a time from the 
original pool of 24 factors and found that there were in fact 10 factors (Fbx15, Nanog, 
ERas, Dppa2, Oct4, Sox2, Tcl1, Klf4, Cttnb1, c-Myc) that either decreased the 
number of generated colonies or resulted in no colonies being formed. Intriguingly, 
introduction of these 10 factors yielded more mouse ESC-like colonies as compared 
to when all 24 factors were used. 
With this smaller pool of factors, Kazutoshi Takahashi and Shinya Yamanaka 
attempted to further narrow down the pool of factors by removing one factor at a time 
from this pool of 10. No colonies were generated when both Oct4 and Klf4 were 
individually removed. The removal of Sox2 yielded very few colonies whereas the 
omission of c-Myc generated colonies which were flattened and did not resemble 
mouse ESCs in terms of their morphology. The exclusion of the other factors however 
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did not elicit any major overt changes. Thus, this was how the Japanese researchers 
discovered the remarkable reprogramming cocktail of Oct4, Sox2, Klf4 and c-Myc. 
 
1.14.2 Screen for factors that could reprogram human fibroblasts 
Despite OSKM being a potent reprogramming cocktail to generate iPSCs, OSKM was 
not the only reprogramming combination reported in the early era of iPSCs. Before 
any group ever succeeded in reporting the first ever generation of human iPSCs, many 
groups were actively trying to derive the first human iPSC, albeit with different 
approaches.  
Jamie Thomson and colleagues first generated a list of factors that were highly 
expressed in human ESCs (with respect to myeloid precursors) as well as their known 
involvement in the maintenance of the ESC identity
51
. Lentiviruses harbouring these 
genes were produced and various combinations of genes were introduced into 
differentiated cells derived from transgenic human ESCs possessing a neomycin-
resistance gene driven by the endogenous POU5F1 promoter. Cells which were 
resistant to G418 indicate that the endogenous POU5F1 loci have been epigenetically 
reprogrammed. Yu et al then homed in on a combination of 14 candidate genes (Table 
2) which could not only reprogram CD45+ hematopoietic derivatives of the 
transgenic human ESCs to drug-resistant cells but also generate human ESC-like 
colonies. 






















   
The authors further narrowed down the pool of 14 factors to only 4 factors - OCT4, 
SOX2, NANOG and LIN28 which can collectively reprogram mesenchymal 
derivatives of the transgenic human ESCs. When either OCT4 or SOX2 were 
removed from the reprogramming cocktail, no drug-resistant colonies were generated. 
Furthermore, both NANOG and LIN28 could individually recover the generation of 
colonies when either OCT4 or SOX2 were omitted.  
Having identified this reprogramming quartet of OCT4, SOX2, NANOG and LIN28, 
Yu and colleagues then embarked on reprograming human fetal fibroblasts with these 
four factors. They were indeed successful in generating human iPSCs and this 
reprogramming quartet became the first non-OSKM reprogramming combination 
reported in the iPSC field.  
It is interesting to note that Nanog was included in Kazutoshi Takahashi and Shinya 
Yamanaka’s screen for reprogramming factors but was not reported as a 
reprogramming factor then. Nonetheless, outside the context of reprogramming, 
Nanog has been implicated to play a role in the maintenance of ESC self-renewal
24,27
. 
Lin28, the other reprogramming factor reported by Thomson and colleagues is neither 
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a transcription factor nor an epigenetic modulator but is instead an RNA-binding 
protein. Lin28 impedes the synthesis of Let7 family of microRNAs
126,127
, which are in 
turn implicated in the self-renewal of breast cancer cells
128
 Interestingly, Lin28 has 
also been reported as an important factor in primordial germ cell development
129
. 
Nevertheless, it is plausible that Lin28 mediates successful reprogramming by 
negatively regulating the differentiation promoting effects of the Let7 family of 
microRNAs. Interestingly, Hanna et al showed that overexpression of Lin28 can 





1.14.3 Screen for factors that could enhance the generation of human iPSCs 
After the discovery of the various reprogramming combinations to derive human 
iPSCs
49,51
, Hongkui Deng and colleagues screened a list of factors in search for 
enhancers of human reprogramming (Table 3). Incidentally, the list of 16 factors 
included reprogramming factors previously reported by the Thomson group
51
 as well 
as short interfering RNAs (siRNAs) against the p53 tumour suppressor gene.  
 
Table 3. List of 16 factors screened by Zhao et al for their potential in 






















 p53 siRNA 
   
Zhao et al performed the screen by introducing each of these factors in combination 
with OSKM into human skin fibroblasts. Alkaline phosphatase (AP) staining was 
performed to quantitate the number of human iPSCs generated. From the screen, the 
authors found that both UTF1 and p53 siRNA can enhance the generation of human 
iPSCs. Strikingly, when both factors were introduced together with OSKM, a 100-
fold enhancement of reprogramming efficiency was achieved as compared to when 
OSKM was used alone.  
Then, Utf1, a factor which is highly expressed in ESCs, was not a new player in the 
field of pluripotency. It was reported that Utf1 is a downstream target of the Oct4-
Sox2 heterodimer and its expression was rapidly curtailed upon differentiation
19
. In 
addition, Utf1 shares many common gene targets with ESC-relevant factors such as 
Oct4, Nanog, Klf4 and c-Myc
132
. Also, Utf1 has been implicated in conferring proper 
chromatin organization in ESCs
132
. p53 siRNA, the other enhancing factor reported in 
the screen by Zhao et al, was later corroborated by several groups to indeed enhance 
the efficiency of reprogramming
133-137
. It was postulated that the p53 pathway poses 
an inhibitory roadbloack to reprogramming and its removal greatly ameliorates the 
poor efficiency of reprogramming
133-137
. Incidentally, p53 is a known tumour 
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suppressor and its ablation which results in an increased proliferation of cells most 
likely accounts for the enhancement in the generation of iPSCs. 
In addition to these factors, other groups have attempted to enhance the efficiency of 
human reprogramming by introducing SV40 large T antigen and the catalytic subunit 
of human telemorase (hTERT)
50,138
. SV40 is known to possess anti-apoptotic 
functions
139
 and is more commonly used in the tumour transformation of cells
140
. 
Notably, the boost in efficiency rendered by SV40 is so high that it has been reported 
that SV40 can even replace Klf4 and Myc in reprogramming
138
. As for hTERT, it was 
previously shown that telomerase activity increased during reprogramming
48,141,142
, 
and its addition is likely to re-create a self-renewing state akin to ESCs. Interestingly, 
in this respect, telomeres have been shown to elongate after reprogramming of 
somatic cells to iPSCs
143
. Nonetheless, it should be noted that proviral genomic DNA 
integration and expression of SV40 and hTERT in derived human iPSCs was not 
detected and thus suggesting possible paracrine effects. 
 
1.14.4 Screen for factors that could replace exogenous Klf4 in reprogramming 
Our group performed a screen back in 2009 in search for factors that could replace 
exogenous Klf4 in the reprogramming of MEFs
85
. We screened 19 factors (Table 4), 
and this list of factors comprises both transcription factors and epigenetic regulators. 
Interestingly, this screen included Klf2, Klf5 and Klf10 which are close family 
members of Klf4. Amongst these krüppel-like factors screened, both Klf2 and Klf5 
have already been previously shown to be able to replace Klf4 in reprogramming by 
Shinya Yamanaka and colleagues
55




Table 4. List of 19 factors screened by Feng et al for their potential in replacing 
exogenous Klf4 in reprogramming
85





















This screen for factors that could replace Klf4 was performed on MEFs harbouring a 
Pou5f1-EGFP transgenic reporter. Unlike, the initial screen conducted by Kazutoshi 
Takahashi and Shinya Yamanaka back in 2006 which identified colonies by drug 
resistance
48
, this screen employed an Pou5f1-EGFP reporter, which more accurately 
labels authentic iPSC colonies
82
. MEFs were transduced with retroviral Oct4, Sox2 
and c-Myc in the presence of each of the candidate factors screened. Typically, MEFs 
transduced with only Oct4, Sox2 and c-Myc would not generate any Pou5f1-EGFP-
positive colonies. However, if Klf4 or any other factor that could functionally replace 
Klf4 were introduced to the three core reprogramming mix, GFP-positive colonies 
would be produced.  
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Surprisingly, Klf10, a Krüppel-like counterpart of Klf4 was unable to replace Klf4 in 
the reprogramming of MEFs. It is noteworthy that not all members of the same family 
could replace their counterparts in reprogramming. For example, Oct1 and Oct6 could 
not replace Oct4 in reprogramming, and Sox7 and Sox17 could not replace Sox2 in 
reprogramming
55
. Remarkably, it has been reported that Sox17 can be converted into 




Strikingly, the screen of potential Klf4 substitutes found that the overexpression of the 
nuclear receptor Esrrb can replace exogenous Klf4 in the reprogramming of MEFs to 
iPSCs. This discovery came as a surprise as Esrrb is not related to the krüppel-like 
transcription factor family, and Esrrb has not been previously implicated in 
reprogramming. Nonetheless, Esrrb has been well reported to play a role in the 
maintenance of mouse ESCs
54
. In addition, we found that Esrrg, a close family 
member of Esrrb, can also replace Klf4 in the reprogramming of MEFs. This finding 
of Esrrb as a reprogramming factor was the first reported finding of a nuclear receptor 
partaking in the generation of iPSCs. 
 
1.14.5  Screen of human transcription factor library  
Using mouse fibroblasts harbouring a GFP reporter driven by the Nanog regulatory 
elements
81
, Shinya Yamanaka and colleagues screened for transcription factors that 
could replace Klf4 in the generation of mouse iPSCs
145
. From a library of 1437 
human transcription factors, they found 18 factors that could replace Klf4 (Table 5), 
albeit at a lower efficiency as compared to when Klf4 is used.  
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Table 5. List of 18 transcription factors discovered by Maekawa et al that can 























Out of these 18 transcription factors, Maekawa et al, found that GLIS1, a maternal 
transcription factor, can enhance the efficiency of OSK reprogramming. In addition, 
both GLIS1 and C-MYC exert a synergistic effect on reprogramming. The authors 
also found that GLIS1 can augment the efficiency of OSK reprogramming in the 
generation of human iPSCs. All in all, this study sheds some light on the ability of 
maternal factors, which are highly expressed in oocytes but lowly expressed in ESCs, 
to play an invaluable role in promoting reprogramming. 
 
1.14.6 Other players in reprogramming: non-coding RNAs 
1.14.6.1 MicroRNAs in reprogramming 
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Besides transcription factors and epigenetic modulators, microRNAs (miRNAs) have 
been recently assigned to play a role in reprogramming. miRNAs are 21-23 
nucleotides-long, non-coding RNAs that can bind to target mRNAs and induce their 
degradation or inhibit their translation to regulate specific cell fate changes
146
.  During 
the early stages of mouse reprogramming, miRNAs (miR) such as miR-17, miR25, 
miR-106a and miR-302b are upregulated
147
. The first miRNA to be implicated in 
reprogramming was miR-302, which is highly expressed in human ESCs
148
. Lin et al 
showed that human skin cancer cell lines can be reprogrammed into cells that highly 
resembled human ESCs after transfection with miR-302 alone
148
. Certain miRNAs are 
also highly expressed in mouse ESCs and they belong to the miRNA-290 cluster, 
which comprise almost three-quarters of the total miRNAs expressed in mouse 
ESCs
149
. Furthermore, miRNAs from the miRNA-290 cluster are rapidly 
downregulated upon ESC differentiation
150
. Notably, these mouse ESC-specific 
miRNAs (miR), miR-291-3p, miR-294 and miR-295, can also enhance the efficiency 
of iPSC generation. Interestingly, this enhancement is achieved only when 
reprogramming occurs with OSK in the absence of c-Myc. c-Myc binds to the 
promoters of these miRNAs and most likely negatively regulates their expression
150
. 
The overexpression of microRNAs belonging to two microRNA clusters (106a-363 
and 302-367) can also enhance the generation of mouse iPSCs in combination with 
OSK
151
. Interestingly, it has been shown that these microRNAs enhance iPSC 
generation by promoting MET changes
151
 which is an important transition in 
reprogramming cells (only when starting from cells of mesenchymal lineage)
78,79
. 
Other miRNAs such as miR-93 and miR-106b, which share the same seed sequence 
have also been shown to enhance OSKM reprogramming by in part targeting Tgf-β 
receptor II and p21
147
.  Remarkably, miR-302-367 cluster of miRNAs was 
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subsequently shown to be able to reprogram mouse and human somatic cells without 
any exogenous factors, with an almost 2-fold increase of efficiency as compared to 
OSKM
152
. Recently, a group has also successfully demonstrated the derivation of 
mouse and human iPSCs with the simple transfection of mature double stranded 
miRNAs (miR-200c, miR-302 and miR-369 family of miRNAs) into somatic cells
153
. 
More recently, a screen of 379 murine miRNAs on the OSK reprogramming of MEFs 
revealed a new family of miRNAs, miR-130/301/721 that enhances reprogramming 




1.14.6.2 LincRNAs in reprogramming 
Besides miRNAs, there are other non-coding RNAs such as the long intergenic non-
coding  RNAs (lincRNAs) can span more than 200 nucleotides
155
. Interestingly, these 
evolutionary-conserved non coding RNAs which are expressed in ESCs
156
, were 
found to be enriched during human reprogramming
157
. Loewer et al discovered 10 
lincRNAs which had a more enriched expression in iPSCs as compared to ESCs. 
These findings suggest that lincRNAs play a mechanistic role in the successful 
derivation of iPSCs. In addition, one of the 10 identified lincRNAs, lincRNA-RoR 
was shown to negatively regulate p53 expression and this is in agreement with reports 
p53 providing a roadblock to reprogramming
158
. Nonetheless, more mechanistic 






1.15. Nuclear receptors 
Prior to my study, Esrrb was the only nuclear receptor implicated in the generation of 
iPSCs
85
. As nuclear receptors belong to a specialised superfamily of proteins it was 
interesting then to investigate if other members contribute to the reprogramming 
process as well. Hence, this sets an impetus for me to screen several nuclear receptors 
for their potential in participating in the reprogramming of somatic cells to iPSCs. 
Nuclear receptors are in principal transcription factors that can sense and respond to 
specific external stimuli such as hormones or molecules, and subsequently modulate 
downstream gene expression by binding to regulatory regions of genes. This 
specialised class of transcription factors thus plays important roles in metabolism, 
embryonic development and the maintenance of homeostasis
159
. The nuclear receptor 
superfamily comprises transcription factors that are either nuclear hormone receptors 
or orphan nuclear receptors
160
. Nuclear hormone receptors, in which their ligands are 
hormonal proteins, include steroid receptors such as estrogen receptor (Esr1), whereas 
examples of orphan nuclear receptors are receptors which have no known endogenous 
ligands, are Esrrb and RORγ. 
Nuclear receptors commonly possess a DNA-binding domain (DBD), a hinge domain, 
and a ligand binding domain (LBD) that is located at the C-terminus. The hinge 
domain connects the DBD and LBD. Besides binding to their respective ligands for its 
activation, the LBD is also involved in dimerisation of the protein (either with itself or 
with another factor).  A nuclear receptor can bind to its ligand in the cytosol or 
nucleus, which typically results in a conformation change in the nuclear receptor. For 
instance, the nuclear receptor can dimerise with itself, dimerise with another nuclear 
receptor or exist and function as a monomer
161
 (Figure 5). Upon activation, nuclear 
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receptors located in the cytosol will then translocate across the nuclear pore and into 
the nucleus and bind to specific sequences of DNA, such as hormone response 
elements (HREs). RNA polymerase enzyme and co-activators will be recruited to 
form a complex with the nuclear receptor and relevant changes in gene expression 
occur to elicit appropriate cellular response (Figure 5). 
  
Wikipedia, (http://en.wikipedia.org/wiki/File:Nuclear_receptor_action.png) 
Figure 5. Mechanism of action of nuclear receptors. External stimuli such as 
hormones enter the cell and bind to the LBD of a nuclear receptor. This binding then 
results in the dissociation of the heat shock protein (HSP) from the nuclear receptor. 
Nuclear receptor may dimerise with another nuclear receptor and translocate through 
the nuclear pore and into the nucleus where it will bind to specific DNA sequences 
such as HREs. Other proteins such as RNA polymerases and coactivators may also be 
recruited to form a complex with the DNA-docked nuclear receptor. Appropriate gene 
expression changes then take place to mediate the appropriate cellular responses.  
 
Nuclear receptors serve diverse roles in myriad cellular processes such as 
development. For instance, the peroxisome proliferator activated receptor γ (PPARγ), 
highly expressed in many tissues, plays a role in the differentiation of cells to 
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macrophages, breast and adipose cell types
162
.   Other nuclear receptors such as germ 
cell nuclear factor (GCNF) play a role in both development and reproduction
163
. 
Besides development and homeostasis, nuclear receptors have also been implicated in 
ESC biology. The retinoic acid receptors (RARs) play a role in mediating retinoic 
acid (RA)-mediated differentiation of ESCs
164
. Interestingly, GCNF is also involved 
in the downregulation of pluripotency genes such as Pou5f1 and Nanog during RA-
mediated differentiation
165
. On the other hand, nuclear receptors also play roles in 
preserving the pluripotent and self-renewal state of ESCs. Esrrb, a transcriptional 
target of both Oct4 and Nanog was found to be important in maintaining the 
pluripotency of mouse ESCs; in its absence, mouse ESCs invariantly differentiate
54
.  
Nuclear receptors have also been implicated in the differentiation of ESCs. For 
instance, loss of Nr5a2 also known as liver receptor homolog-1 (Lrh-1) in mouse 
ESCs, results in a more rapid differentiation outcome upon RA-treatment as compared 
to WT ESCs
166
. Another factor implicated in the maintenance of ESC pluripotency is 
Dax1, an interacting partner of Nanog
167
. Differentiation results when Dax1 is 
knocked down in ESCs
167




All in all, nuclear receptors are involved either in homeostasis, development or ESC 
biology, and prior to this study only Esrrb has been implicated in reprogramming. 
Hence, to identify more nuclear receptor players in reprogramming, a screen for 
nuclear receptors for their ability to enhance reprogramming or replace core 





2. Materials and Methods 
2.1 Cell culture 
iPSCs were generated and cultured on mitomycin C-inactivated CD1 MEF feeders. 
15% FBS-DMEM (Gibco) media supplemented with 1 mM L-glutamine was used in 
the culturing of MEFs. mESC media comprising 15% FBS-DMEM media 
supplemented with 0.1 mM β-mercaptoethanol , 1 mM L-glutamine, 1% non-essential 
amino acids (all from Gibco) and mouse LIF (1000 U/ml, home-made) was used in 
the culturing of  mouse ESCs and the initial reprogramming phase (2 dpi to 6 dpi). At 
7 dpi onwards, mouse ESC media was supplemented with 15% knockout serum 
replacement (KOSR) instead of FBS. PLAT-E cells were cultured in 10% FBS-
DMEM media supplemented with 1 mM L-glutamine, blasticidin S HCL (Invitrogen) 
and puromycin (Sigma).  293-T, GP-293-T and MRC-5 (ATCC) cells were cultured 
in 10% FBS-DMEM media supplemented with 1 mM L-glutamine. All cell types 
stated above were passaged with 0.125% trypsin (in-house). Human ESCs and human 
iPSCs were grown in mTeSR1 media (STEMCELL Technologies) and on Matrigel 
(BD Biosciences)-coated plates. Human ESCs and iPSCs were passaged with 1 mg 
ml
-1




To investigate protein expression from vectors, 293-T cells were transfected with 
respective pMX retroviral plasmids in media supplemented with Lipofectamine 2000 
(Invitrogen) and Opti-MEM I (Gibco) according to the manufacturer’s protocol. For 
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gene knockdown experiments, pSUPER.puro plasmids harbouring the appropriate 
shRNA constructs were transfected into mouse ESCs in media supplemented with 
Lipofectamine 2000 (Invitrogen) and Opti-MEM I (Gibco). Transfected cells were 
selected for with 1 μg ml-1 of puromycin 16 h after transfection. shRNA sequences are 
as follows: 




2.3 Mouse genetics 
MEFs were harvested from E13.5 embryos generated from the intercross between 
actin-GFP male mice (Jackson’s Laboratoy, stock number 003516) with female wild 
type CD1 mice, and Pou5f1-EGFP transgenic male mice (Jackson’s Laboratoy, stock 
number 004654) with female WT 129S2/SV mice. p53 WT, HET and KO MEFs were 
kindly donated by Dr Lim Bing’s laboratory. iPSCs were dissociated into single cells 
and 10-12 cells were microinjected into 8-cell stage embryos of the C57BL/6J and 
B6(Cg)-Tyr
c-2J/J 
background. Microinjected embryos were implanted into the oviduct 
of E0.5 pseudopregnant F1 (CBA x C57BL/6J) females. E13.5 chimeric embyros 
were harvested and checked for GFP expression in the gonads. To assay for germline 










2.4 Packaging of retroviruses and infection 
cDNA sequences of genes were PCR-amplified from commercial plasmids (Open 
Biosystems) or mouse ESC cDNA. PCR primers are as follows: 
Dax1: 5’-GAAGGATGTGGTTCGAGTA-3’ (forward) 
Dax1: 5’-CTGTCGACTCACAGCTTTGCACAGAGCATC-3’ (reverse) 
Rara: 5’-ATGGATCCGCCACCATGGCCAGCAATAGCAGTTCC-3’ (forward) 
Rara: 5’-CTGTCGACTCATGGGGATTGGGTGGCTG-3’ (reverse) 
Rarg: 5’-AGAGAGGATCCATGGCCACCAATAAGGAGAG-3’ (forward)  
Rarg: 5’-AGAGAGTCGACTCAGGGCCCCTGGTCAGGTT-3’ (reverse) 
Rev-erba: 5’-ATGGATCCGCCACCATGCGACCCTGGACTCCATAA-3’ (forward) 
Rev-erba: 5’-CTGTCGACTCACTGGGCGTCCACCCGGA-3’ (reverse) 
Lxrb: 5’-ATGGATCCGCCACCATGTCTTCCCCACAAGTTC-3’ (forward) 
Lxrb: 5’-CTGTCGACCTACTCGTGCACATCCCAGATCTC-3’ (reverse) 
Lxra: 5’-ATGGATCCGCCACCATGTCCTTGTGGCTGGAGGC-3’ (forward) 
Lxra: 5’-CTCTCGAGTCACTCGTGGACATCCCAGATC-3’ (reverse) 
Vdr: 5’-AGAGGATCCACCGCCATGGAGGCAATGGCAGCCAG-3’ (forward) 
Vdr: 5’-AGAGAGTCGACTCAGGAGATCTCATTGCCGAACAC-3’ (reverse) 
Nr1i2: 5’-AGAGAGAATTCAGATGAGACCTGAGGAGAGCTG-3’ (forward) 





Car: 5’-AGAGAGTCGACTCAACTGCAAATCTCCCCGA-3’ (reverse) 
Rora: 5’-ATGGATCCGCCACCATGAAGCTCAAATTGAAATTATTC-3’ 
(forward) 
Rora: 5’-CTGTCGACTTACCCATCGATTTGCATGGC-3’ (reverse) 
Hnf4a: 5’-ATGGATCCGCCACCATGCGACTCTCTCTAAAA-3’ (forward) 
Hnf4a: 5’-CTGTCGACCTAGATGGCTTCTTGCTTGGTGATC-3’ (reverse) 
Rxra: 5’-AGAGAAGATCTATGGACACCAAACATTTCCT-3’ (forward) 
Rxra: 5’-AGAGAGTCGACCTAGGTGGCTTGATGTGGTG-3’ (reverse) 
Tlx: 5’-ATGGATCCGCCACCATGAGCAAGCCCGCCGGATC-3’ (forward) 
Tlx: 5’-CTCTCGAGTTAGATGTCACTGGATTTGTACATATC-3’ (reverse) 
Pnr: 5’-ATAGATCTGCCACCATGAGCTCTACAGTGGCTGCCT-3’ (forward) 
Pnr: 5’-CTGTCGACCTAGTTTTTGAACATGTCACACAGG-3’ (reverse) 
Ear2: 5’-ATGGATCCGCCACCATGGCCATGGTGACCGGTGG-3’ (forward) 
Ear2: 5’-CTGTCGACCTAGCCCGAGCCATAGGGCC-3’ (reverse) 
Esrra: 5’-AGAGAGGATCCATGTCCAGCCAGGTGGTGGG-3’ (forward) 
Esrra: 5’-AGAGAGTCGACTCAGTCCATCATGGCCTCAA-3’ (reverse) 
Esrrb: 5’-AGAGAGGATCCATGTCGTCCGAAGACAGGCA-3’ (forward)    
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Esrrb: 5’-AGAGAGTCGACTCACACCTTGGCCTCCAGCA-3’ (reverse) 
Esrrg: 5’-AGAGATGATCAATGGATTCGGTAGAACTTG-3’ (forward) 
Esrrg: 5’-AGAGAGTCGACTCAGACCTTGGCCTCCAGCA-3’ (reverse) 
Nr5a1: 5’-ATGGATCCGCCACCATGGACTATTCGTACGACGAGGA -3’ 
(forward) 
Nr5a1: 5’-CTCTCGAGTCAAGTCTGCTTGGCCTGCA- 3’ (reverse) 
Nr5a2: 5’-AGAGAGGATCCATGTCTGCTAGTTTGGTAC-3’ (forward) 
Nr5a2: 5’-AGAGAGTCGACTTAGGCTCTTTTGGCATGCA-3’ (reverse) 
Mtf2: 5’-AGAGAGGATCCATGAGAGACTCTACAGGAGC-3’ (forward) 
Mtf2: 5’-AGAGAACGCGTTCAGGATGCAGTCGCTCCTT-3’ (reverse) 
DNA and ligand binding mutants of Nr5a2 were created by PCR with primers 
harbouring the relevant point mutations within their sequences. cDNA sequences of 
Nr5a2 2KR and 5KR sumoylation mutants were PCR-amplified from donated 
plasmids
169
. PCR-amplified gene sequences were cloned into MMLV-based pMX 
retroviral vector and sequence verified. shRNA knockdown sequences in addition to 
their promoters were restriction enzyme-digested from pSUER.puro vectors and 






MEM 1 media (Invitrogen). For packaging of retroviruses for human cell infection, 
GP-293-T cells were used and VSVG packaging plasmid is used in addition to the 
above-mentioned transfection reactions and plasmids. Retrovirus-containing media 
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that was harvested was filtered and concentrated with centrifugal filter units 
(Millipore).  
For quantitation of viruses, 3T3 cells were infected with retroviruses that were 
packaged with the GFP gene. At 2 dpi, number of GFP-positive cells was determined 
with FACs. Calculation of the number of transducing units
171
 is as follows: 
Transducing units (µl) = [[(Percentage of GFP-positive cells) x (Number of 
cells seeded)]/(100 x Volume of dilution )] x 1/Dilution factor 
A multiplicity of infection (MOI) of 5 was used
98
 for the infection of MEF and the 
amount of virus used for each infection is calculated as follows: 
Transducing units required = (MOI = 5) x (Number of cells seeded) 
Amount of virus needed = Transducing units required /Transducing units (ml) 
MEFs were infected with the respective viruses at 65% confluence in polybrene (6 ng 
ml
-1
, Invitrogen)-supplemented 15% FBS-DMEM medium. 24 h after infection, 
media was replaced with fresh medium. 48 h after infection, infected cells were 
passaged to CD1 MEF feeders and cultured in mouse ESC medium. At 7 dpi onwards, 
KSR-containing mouse ESC medium was used. For human reprogramming, 5 MOI of 
retroviruses were used to infect MRC-5 cells in MEMα media supplemented with 
10% FBS, and infection media is changed the next day. Infected cells are passaged on 






2.5 PCR genotyping of retroviral integration into the genome 
Cells were trypsinised, pelleted and resuspended with PKDB buffer supplemented 
with Proteinase K (Fermentas). Genomic DNA was isolated with phenol-chloroform 
extraction and precipitated with isopropanol. iPSC or embryo genomic DNA (300 ng) 
was harvested and used for each PCR genotyping. Genomic DNA from ESCs and 
MEFs were used as controls. The forward primer was designed based on sequences in 
the 5’ region of the pMX vector, before the gene proper region, while the reverse 
primers used were sequences belonging to gene-specific regions of the relevant 
reprogramming genes.  
pMX-specific primer: 5’-GACGGCATCGCAGCTTGGATACAC-3’ (forward) 
Nr5a1: 5’-CAGCTCTCGCACGTGAGCAG-3’ (reverse) 
Nr5a2: 5’-GACGCAATAGCTGTAAGTCCATG-3’ (reverse) 
Pou5f1: 5’-CCAATACCTCTGAGCCTGGTCCGAT-3’ (reverse) 
Sox2: 5’-GCTTCAGCTCCGTCTCCATCATGTT-3’ (reverse) 
Klf4: 5’-GCCATGTCAGACTCGCCAGG-3’ (reverse) 
c-Myc: 5’-TCGTCGCAGATGAAATAGGGCTG-3’ (reverse) 
 
2.6 Bisulphite genomic DNA sequencing 
After bisulphite treatment of genomic DNA with the Imprint
TM
 DNA modification kit 
(Sigma), specific regions of the promoters of Pou5f1 and Nanog were PCR-amplified 
and cloned into the pCR2.1-TOPO vector (Invitrogen). Universal primers, M13 
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forward and M13 reverse were used to verify the sequence of the amplified promoter 
regions. Sequences of the primers used in the PCR amplification are as follows: 
Pou5f1: 5’-ATGGGTTGAAATATTGGGTTTATTTA-3’ (forward) and  
 5’-CCACCCTCTAACCTTAACCTCTAAC-3’(reverse) 
Nanog: 5’-GATTTTGTAGGTGGGATTAATTGTGAATTT-3’ (forward) and  
               5’-ACCAAAAAAACCCACACTCATATCAATATA-3’ (reverse) 
 
2.7 Embryoid body formation and in vitro differentiation  
iPSCs were dissociated into single cells with trypsin, seeded onto Petri dishes and 
cultured for 5 days in mouse ESC medium lacking LIF and β-mercaptoethanol. 
Formed EBs were then cultured in gelatin-coated wells for 5 days in the presence of 1 
µM retinoic acid (Sigma). After which, differentiated samples were fixed with 4% 
paraformaldehyde, membrane-permeabilised with 1% triton X-100 and blocked with 
8% FBS. Primary antibodies targeting Gata4 (1:100, sc-25310, Santa Cruz), α-smooth 
muscle actin (1:100, ab18460, Abcam) and Nestin (1:100, sc-58813, Santa Cruz) were 
introduced before staining with the Alexa Fluor 546-conjugated anti-mouse secondary 
antibody (1:1000, Invitrogen). Nuclei were then stained with Hoechst dye (1:4000, 
Invitrogen). 
 
2.8 Teratoma formation assay 





). The cell suspension (100 µl) was then subcutaneously 
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injected into both dorsal flanks of SCID mice, which were anesthetised with avertin. 
After 4 weeks, teratomas were dissected from sacrificed mice and weighed. 
Teratomas were then fixed in Bouin’s solution, embedded in paraffin, sectioned and 
stained with Mallory’s Tetrachrome.172 
 
2.9 TUNEL apoptosis assay  
Retroviral-infected MEFs were trypsinised and subjected to TUNEL apoptosis assay 
at 3 dpi. Uninfected MEFs that were treated with DNase1 (Ambion) was used as a 
positive control. Cells were fixed and subjected to TUNEL labelling with a 
commercial kit according to the manufacturer’s instructions. Labelled cells were then 
analysed using FACs. 
 
2.10 Western blot analysis 
MEFs and ESCs were lysed with RIPA buffer (Pierce) in the presence of protease 
inhibitor (Roche). Concentration of protein was determined with a Bradford assay kit 
(Bio-Rad) before samples (50 µg) were resolved on a 10% SDS-polyacrylamide gel. 
Resolved proteins were transferred to a polyvinylidine difluoride membrane 
(Millipore) and blocked with 5% skim milk. Primary antibodies against actin (1:2000, 
sc-1616, Santa-Cruz), HA (1:2000, sc-7392, Santa Cruz) or Nr5a2 (1:2000, ab18293, 
Abcam) was added and incubated for 1 h.  Blot was then washed with PBST and 
horse-radish peroxidase (HRP)-conjugated secondary antibodies, anti-goat IgG 
(1:5000, sc-2768, Santa Cruz), anti-mouse IgG (1:5000, 1858413, Pierce) and anti-
rabbit IgG (1:5000, sc-2004, Santa Cruz) were respectively introduced and incubated 
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for 1 h. After incubation, blot was washed with PBST and signals were visualised 
with the Western Blotting Luminol reagents (Santa Cruz). 
 
2.11 Southern blot analysis 
10 µg of genomic DNA was digested with the appropriate restriction enzymes 
overnight and digested DNA was resolved on an ethidium bromide-free agarose gel 
overnight. Gel was then pre-treated with 0.25 M HCl for 10 min and then washed 
twice in 0.5 M NaOH for 30 min. Gel was then transferred onto a nylon membrane 
and left overnight for transfer. Membrane was washed with 5X SSC for 10 min with 
agitation and then incubated in pre-hybridisation solution with agitation for 4 hours at 
42 ºC. Pre-hybridisation solution is removed and hybridisation solution comprising 
heated DIG-labelled probe was prepared and added to the membrane at 42 ºC for 
overnight incubation. Membrane was washed with 2X SSC, 0.1% SDS for 5 min and 
then with 0.5X SSC, 0.1% SDS at 53ºC. After washing, membrane was blocked with 
1X blocking solution for 30 min and anti-DIG antibody (1:10,000) was added and 
incubated with membrane for 30 min. After incubation, membrane was washed with 
1X MABT for 15 min and then equilibrated with detection buffer for 5 min. CSPD 
was added for 5 min and then removed. Membrane was dried at 37 ºC for 10 min and 
then exposed to film.  
 
2.12 Immunofluorescence and alkaline phosphatase staining 
iPSCs were fixed with 4% paraformaldehyde, permeabilised with 1% triton X-100, 
blocked with 8% FBS and stained with primary antibodies targeting SSEA1 (1:200, 
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MAB4301, Chemicon) and Nanog (1:50, RCAB0002PF). After 1 h incubation, cells 
were washed with PBST and secondary antibody, Alexa Fluor 568 conjugated anti-
rabbit (1:300, Invitrogen) and Alexa Fluor 546 conjugated anti-mouse IgM (1:2000, 
Invitrogen) were respectively introduced. After 1 h of incubation with the secondary 
antibodies, cells were washed and nuclei were stained with Hoechst dye (Invitrogen). 
For AP staining, iPSCs and ESCs were fixed with 4% paraformaldehyde and blocked 
with 8% FBS before AP was detected using a commercial AP detection kit 
(Chemicon). 
 
2.13 RNA extraction, reverse transcription and quantitative real-time PCR 
Total RNA was extracted with chloroform and isopropanol from cells that were 
harvested with Trizol (Invitrogen). RNA was then subjected to DNase I (Ambion) 
treatment to remove any contaminating DNA and purified with the RNAeasy column 
(Qiagen). cDNA was generated with the reverse transcription of 500 ng of RNA using 
oligo (dT) 18 primers and Superscript II (Invitrogen). Quantitation of gene mRNA 
level was carried out with quantitative real-time PCR of the obtained cDNA with Sybr 
green reagents (Kappa). Measured transcripts were normalised to the expression level 
of actin. Quantitative real-time PCR analyses were performed using an ABI PRISM 
7900 Sequence Detection System. The conditions are as follows: initiation step at 
95°C for 10 min, elongation step at 95°C for 30 s, 60°C for 30 s, 72°C for 1 min, and 
primer dissociation step at 95°C for 15 s, 60°C for 1 min and 95°C for 15 s.  Real time 
PCR was used to verify the overexpression of each of the nuclear receptor. The 




Dax1: 5’-CGTGAGCGCAGACCAAACAC-3’ (forward) 
Dax1: 5’-AGCGCAGGGTCTTCAACAGG-3’ (reverse) 
Rara: 5’-CAAAGCGCACCAGGAGACCT-3’ (forward) 
Rara: 5’-AGCTGCTTGGCGAACTCCAC-3’ (reverse) 
Rarg: 5’- TGGCCACCAAATGCATCATC-3’ (forward)  
Rarg: 5’-GCATCTGGGTTCGGTTCAGG-3’ (reverse) 
Rev-erba: 5’-ACACCGCTGGGAGAGTCAGG-3’ (forward) 
Rev-erba: 5’-AGACGGTGCCCATTGCTGTT-3’ (reverse) 
Lxrb: 5’-CGTGCCTGGGAATGGTTCTC-3’ (forward) 
Lxrb: 5’-GGAAGCCCGAAGCCTTGTCT-3’ (reverse) 
Lxra: 5’-GCGGAAATGCCAGGAGTGTC-3’ (forward) 
Lxra: 5’-GCAGCCACCAGCTTCTCGAT-3’ (reverse) 
Vdr: 5’-ACTTCCGGCCTCCAATTCGT-3’ (forward) 
Vdr: 5’-CAGCATGGAGAGCGGAGACA-3’ (reverse) 
Nr1i2: 5’-TGCAGGCCATCTCCCTCTTC-3’ (forward) 
Nr1i2: 5’-GGACGGCCATGATCTTCAGG-3’ (reverse) 
Car: 5’-ATGGGCCGAGGAACTGTGTG-3’ (forward) 
Car: 5’-AGGCTGGACAGTGGCGTCTC-3’ (reverse) 
Rora: 5’-CAACCGTGTCCATGGCAGAA-3’ (forward) 
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Rora: 5’-ATGGCACACAGCTGCCACAT-3’ (reverse) 
Hnf4a: 5’-GCGACATTCGGGCAAAGAAG-3’ (forward) 
Hnf4a: 5’-GGTGGCTCCAAGCAGCAGAT-3’ (reverse) 
Rxra: 5’-TGCTGTCGAGCCCAAGACTG-3’ (forward) 
Rxra: 5’-GGAGAAGGAGGCGATCAGCA-3’ (reverse) 
Tlx: 5’-CAGCTCCGGGAAGCACTACG-3’ (forward) 
Tlx: 5’-TGCTGCACGGCATCTTTGTT-3’ (reverse) 
Pnr: 5’-GTTCCGAGCTCTGGCAGTGG-3’ (forward) 
Pnr: 5’-GATGGGAGCAGGAGGAGCAA-3’ (reverse) 
Ear2: 5’-CCTGATGCCTGTGGCCTTTC-3’ (forward) 
Ear2: 5’-GAAGCATGTCCCGGATGAGG-3’ (reverse) 
Esrra: 5’-CAAACGCCTCTGCCTGGTCT-3’ (forward) 
Esrra: 5’-GCGTCTCCGCTTGGTGATCT-3’ (reverse) 
Esrrb: 5’-GTACCGCTCGCTCCCATACG-3’ (forward)    
Esrrb: 5’-CCGCCTCCAGGTTCTCAATG-3’ (reverse) 
Esrrg: 5’-CGCATTTGTTGGTGGCTGAA-3’ (forward) 
Esrrg: 5’-TGCCAGGGACAGTGTGGAGA-3’ (reverse) 
Nr5a1: 5’-GCCAGGTCCAGTACGGCAAG -3’ (forward) 
Nr5a1: 5’-TTCCTGGGCGTCCTTTACGA- 3’ (reverse) 
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Nr5a2: 5’-CTGGTGGTGAGGCTCCGTTC-3’ (forward) 
Nr5a2: 5’-TCTGCCTGCTTGCTGATTGC-3’ (reverse) 
Mtf2: 5’-GAAGAGGTCGCCTTCCACGA-3’ (forward) 
Mtf2: 5’-CCTTCCCATCAAGCGTCACC-3’ (reverse) 
 
2.14 G-banded karyotyping 
iPSCs treated with colcemid (Invitrogen) and harvested with standard hypotonic 
treatement were fixed with methanol-acetic acid (3:1 proportion). Air-dried slides 
were then used for G-banded karyotyping analysis.  
 
2.15 Microarray experiment and analysis 
cDNA was obtained from the reverse transcription of total RNA isolated from iPSCs 
(#A5, #B3, #B11, OSKM and N2OSKM), ESCs and MEFs (Pou5f1-EGFP and actin-
GFP) with a commercial cDNA kit (Ambion) according to the manufacturer’s 
instructions. Microarray experiment for transcriptome comparison of obtained iPSCs 
with mESCs and MEFs was performed with biological duplicates for each cell line. 
Microarray experiment for transcriptome comparison of OSKM-iPSCs with N2OSKM 
was performed with biological triplicates for each cell line. cDNA was hybridised and 
processed onto the microarray chip (Sentrix Mouse-6 Expression BeadChip version 
1.1) according to the manufacturer’s protocol. Chips were scanned with an Illumina 
microarray scanner. Differentially expressed transcripts were determined based on 
Significance Analysis of Microarrays
173
 with criteria as follows: fold change (FC) < 
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0.6 for downregulated, FC > 1.5 for upregulated; q value < 0.02; and detection 
probability greater than 0.95 in every samples. 
 
2.16 ChIP assay  
Cells were cross-linked with 1% formaldehyde for 10 min at room temperature before 
formaldehyde was quenched with 125 mM glycine. Cells lysates were subjected to 
sonication and immunoprecipitation of chromatin extracts was performed with anti-
HA (sc-7392, Santa Cruz), anti-H3K4me3 (ab8580, Abcam) or anti-H3K27me3 (07-
449, Millipore) antibodies. Quantitative real-time PCR was then carried out to 
determine the degree of protein-DNA interaction.  
 
2.17 ChIP-sequencing and analysis 
The specificity of the HA-antibody used for the ChIP-seq of Nr5a2 was verified by 
western blot (Figure 31A). The HA-antibody recognised a distinct band of the right 
protein size in 3HA-Nr5a2 mouse ESC extract. 10 ng of ChIP DNA was end-polished 
with T4 DNA polymerase and kinase followed by the addition of an adenine base 
before purification with the Qiaquick column was performed. Solexa adaptors were 
ligated to the ChIP DNA fragments and 15 cycles of PCR was performed to enrich 
them. 150-300 bp size fractions were selectively cut out from the gel, and eluted by 
Qiagen gel extraction kit. The extracted DNA was quantified by PicoGreen assay 




Peak calling of the ChIP-seq data of Nr5a2 in mouse ESCs (8,023 427 uniquely 
mapped tags) was performed using MACS with a p-value cutoff of 1e-9, and 3,346 
peaks were obtained. ChIP-seq data of anti-HA was used as a control 
(13,001,272 uniquely mapped tags). Enriched motifs were determined by MEME, a 
de novo motif discovery tool utilising 200-bp sequences centered on the peaks. For 
co-occurrence analysis, ChIP-seq profile for each binding factor was first expressed as 
the peak position and a combined list of positions was generated by merging the lists 
of individual peaks. Distance from one site to the closest site of any type was 
determined. Pairs of sites within 50 bp of one another were categorised to the same 
group. According to these groups, the number of times each transcription factor 
occurred together with every other transcription factor in the same group was 
determined. These calculations yielded a co-localisation vector for every transcription 
factor. Pearson correlation coefficient for each co-localisation vector pair was 
calculated and used as a similarity measure to cluster the transcription factors based 
on the default distance definition and clustering algorithm in the “heatmap” function 
of R. 
 
2.18 Gene targeting of POU5F1 locus by homologous recombination 
A human BAC (CTD-3206G17, Invitrogen) covering the POU5F1 gene was modified 
via recombineering with the insertion of an EGFP-pA-FRT PGK-neo FRT cassette at 
the start codon of the POU5F1 gene. A linearised modified BAC construct with a 
73.3 kb long arm and a 16.0 kb short arm was created by restriction digestion with 
Acl1 and Fse1 enzymes. Linearised constructs were electroporated into dissociated 





). Correctly-targeted cell lines were verified via long range PCR (Qiagen) 



























3.1 Setting up of the reprogramming assay  
Capitalizing on the discovery that the nuclear receptor, Esrrb can replace Klf4 in the 
generation of mouse iPSCs
85
, I decided to investigate if other nuclear receptors could 
also contribute to the reprogramming process. As reprogramming with nuclear 
transfer and cell fusion occurs at a considerably more accelerated and efficient fashion 
(as they involve the transferring of the entire complement of nuclear regulators seen in 
ESCs) than reprogramming with transcription factors
174
, the reprogramming factor 
combination of OSKM is arguably an inaccurate representation of the complete milieu 
of transcription factors needed to mediate fast and complete reprogramming. In 
addition, there might be factors not found in the typical ESC milieu that could also 
augment reprogramming. To this end, I performed a screen of nuclear receptors in 
search for more factors that could enhance the generation of mouse iPSCs. MEFs, 
harvested from E13.5 embryos derived from Pou5f1-EGFP mice were used in my 
reprogramming assays. These transgenic MEFs harbour a GFP reporter (Figure 6) and 
the regions upstream of this GFP reporter comprise an 18 kb stretch of the Pou5f1 
regulatory element that include the Pou5f1 promoter and Pou5f1 distal enhancer but 
without the Pou5f1 proximal enhancer
175
 (Figure 6). These cells that were used for the 
reprogramming assays are henceforth called Pou5f1-EGFP MEFs.  
     
                        
Figure 6. The Pou5f1-EGFP reporter harboured by the MEFs that were used in 
the reprogramming assay. MEFs were harvested from E13.5 Pou5f1-EGFP mice 
embryos. These transgenic cells harbours the Pou5f1-EGFP reporter, in which EGFP 
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expression is driven by 18 kb stretch of regulatory elements comprising the Pou5f1 
promoter and enhancer regions minus the proximal enhancer. 
 
cDNA sequences of my candidate nuclear regulators were cloned into the pMX 
retroviral vector and transfected into PLAT-E retrovirus packaging cells
170
 to generate 
retroviruses for infection (Figure 7). Pou5f1-EGFP MEFs were then infected with 
concentrated retroviruses and then transferred into mouse ESC media throughout the 
timeline of reprogramming to select for and cultivate iPSCs (Figure 7). Quantitation 
of Pou5f1-EGFP-positive colonies is typically done at 14 dpi (Figure 7). 
 
 
Figure 7. Schematic diagram showing the reprogramming protocol employed for 
the generation of mouse iPSCs. Genes were first cloned into the pMX retroviral 
vectors and sequenced verified. pMX plasmids were transfected into PLAT-E cells for 
packaging for retroviruses. Harvested retroviruses were then concentrated. MEFs 
were infected with relevant retroviruses. At 2 dpi, the infected MEFs are then 
passaged onto MEF feeder cells and mouse ESC media is used. At 6 dpi onwards, 
KSR-based mouse ESC media is used instead. AP-staining could be performed at 9 
dpi. However, quantitation of Pou5f1-EGFP iPSC colonies, which is a better method 




When these Pou5f1-EGFP MEFs were transduced with OSKM retroviruses, 
reprogramming occurs. At around 10 dpi, GFP expression is observed in mouse iPSC 
colonies (Figure 8). The expression of GFP is indicative of the re-activation of the 
silenced Pou5f1 locus and hence better iPSC colonies can be selected for from the rest 
based on this reliable turning on of the endogenous Pou5f1 expression. 
 
                            
Figure 8. Transduction of Pou5f1-EGFP MEFs with OSKM retroviruses. 
Pou5f1-EGFP MEFs were infected with OSKM retroviruses. iPSC colonies that were 
formed displayed green fluorescence indicating activation of the endogenous Pou5f1 
locus. Uninfected MEFs which should not be reprogrammed are shown as a negative 
control. Scale bar represents 200 µm.  
 
A list of 19 murine nuclear receptors (Table 6) were cloned into the pMX retroviral 
plasmid and retroviruses harbouring these genes were packaged with the PLAT-E 
virus packaging cells
170
. MEFs were then individually infected with these packaged 
retroviruses and the RNA was harvested to determine the proper expression of these 
nuclear receptor genes from the integrated retroviruses. PCR performed with a pMX-
specific primer and a gene-specific primer using the derived cDNA shows that nuclear 
receptor gene transcripts are indeed overexpressed after retroviral infection of the 















Nr0b1 (Dax1) Transcriptional repressor of several nuclear receptors 
  
Nr1b1 (Rara) Regulator of Pou5f1 
  




Regulator of circadian and metabolic pathways 
  
Nr1h2 (Lxrb) Regulator of lipid and cholesterol homeostasis 
  
Nr1h3 (Lxra) Regulator of lipid and cholesterol homeostasis 
  
Nr1i1 (Vdr) Mediator of vitamin D 
  
Nr1i2 (Pxr) Regulator of cytochrome P450 
  
Nr1i3 (Car) Regulator of cytochrome P450 
  
Nr1f1 (Rora) Regulator of metabolic homeostasis 
  
Nr2a1 (Hnf4a) Regulator of liver-specific genes 
  
Nr2b1 (Rxra) Role in ESC differentiation to cardiomyocyte 
  
Nr2e1 (Tlx) Role in neurogenesis 
  
Nr2e3 (Pnr) Transcriptional repressor of cone-specific genes 
  
Nr2f6 (Ear2) Transcriptional repressor of IL-17 in T-cells 
  
Nr3b1 (Esrra) Role in osteoblast development 
  
Nr3b2 (Esrrb) Self-renewal regulator, reprogramming factor 
  
Nr3b3 (Esrrg) Reprogramming factor 
  
Nr5a2 (Lrh-1) Activator of Pou5f1 
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Figure 9. Gene expression of nuclear receptors that were cloned into the pMX 
retroviral vector. Expression was verified by PCR amplification of cDNA with a 
virus-specific primer and a gene-specific primer.  
 
 
3.2 Screen of nuclear receptors in reprogramming reveals Nr5a2 and Nr1i2 as 
enhancers 
 
A screen of nuclear receptors for their potential to enhance reprogramming was 
carried out. To test if single nuclear receptors could potentiate iPSC reprogramming 
efficiency, Pou5f1-EGFP MEFs were transduced with an individual nuclear receptor 
atop the conventional OSKM cocktail to test if any further gains in reprogramming 
efficiency were afforded above OSKM alone. Quantitation of the number of Pou5f1-
EGFP-positive iPSC colonies was performed at 14 dpi. From my reprogramming 
enhancer screen, I found two nuclear receptors, Nr1i2 and Nr5a2 that can enhance the 







Figure 10. Screen of nuclear receptors in search for enhancers of 
reprogramming. 19 nuclear receptors were screened for their ability to enhance the 
efficiency of reprogramming in combination with OSKM. Pou5f1-EGFP MEFs 
transduced with OSKM was used as a control. Number of GFP-positive colonies was 
quantitated at 14 dpi. Data represent mean ± SEM of three independent transduction 
experiment (n=3).  
 
3.3 Nr5a2 enhances both the efficiency and kinetics of reprogramming 
To investigate if Nr1i2 and Nr5a2, which enhance reprogramming efficiency, can also 
enhance the kinetics of reprogramming, I quantitated the number of Pou5f1-EGFP-
positive colonies during the initial stages of reprogramming when Nr1i2 and Nr5a2 
are introduced. From the time course reprogramming assay, when Nr1i2 is introduced 
together with OSKM, GFP-positive colonies do not appear earlier than with OSKM 
alone (Figure 11). However, when MEFs are transduced with Nr5a2 and OSKM, the 
first GFP-positive iPSC colonies appear about 3 days earlier than with OSKM alone 
(Figure 11). This shows that Nr5a2 can not only enhance the efficiency of 
reprogramming but can also augment the kinetics of reprogramming.  
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Figure 11. Time-course reprogramming assay with enhancers of 
reprogramming. Reprogramming enhancers, Nr5a2 and Nr1i2 were investigated for 
their ability to also enhance reprogramming kinetics.  Throughout the process of 
reprogramming, the number of GFP-positive iPSC colonies were quantitated until 11 
dpi to investigate the kinetics of reprogramming. OSKM was used as a control. Data 
represent mean ± SEM of three independent transduction experiment (n=3). 
 
To investigate if introduction of either Nr1i2 or Nr5a2 effects cell viability, I 
performed TUNEL assay, a common measure of cell apoptosis. When TUNEL dye 
was added to MEFs transduced with Nr1i2 and Nr5a2, no TUNEL-positive cells were 
observed (Figure 12A). Similarly, FACS sorting of Nr1i2 and Nr5a2-infected MEFs 
did not detect any TUNEL-positive cells (Figure 12B) hence indicating that both 
nuclear receptors do not negatively affect cell viability.  
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Figure 12. TUNEL assay of Nr1i2 and Nr5a2-infected MEFs. (A) MEFs were 
transduced with Nr1i2 and Nr5a2 and tested for apoptosis with the TUNEL assay. The 
pMX vector which do not harbour any cloned genes was also introduced into MEFs as 
a negative control.  Cells were treated with DNase I to induce cell death and these 
samples were used as a positive control.  Green represents TUNEL-positive cells. 
Inset images represent brightfield images. Scale bar represents 200 µm. (B) Graph 
depicting percentage of TUNEL-positive cells after FACS analysis. For positive 
control, uninfected MEFs were treated with DNase I before TUNEL labelling. Data 
represent mean ± SEM of three independent transduction experiment (n=3).  
 
 
3.4 Nr5a2 can replace exogenous Oct4 in reprogramming 
 
Next, I was interested to investigate if these enhancers of reprogramming could 





, I focused on interrogating whether either of these 
two reprogramming enhancers could replace Oct4, Sox2 or Klf4. From my 
reprogramming assay, I found that Nr1i2 was unable to replace Oct4, Sox2 and Klf4 
(Figure 13). The other reprogramming enhancer, Nr5a2 was unable to replace Sox2 
and Klf4 (Figure 13). Saliently, when MEFs were transduced with Nr5a2 in addition 
to SKM retroviruses, GFP-positive iPSC colonies (23.7 ± 3.5 iPSC colonies per 
100,000 MEFs plated) were observed (Figure 13 and Figure 14A-B). This therefore 
demonstrated that Nr5a2 can replace exogenous Oct4 in the reprogramming of MEFs 
to iPSCs. 
                    
 
                      
Figure 13. Reprogramming assay to investigate the ability of the reprogramming 
enhancers in substituting Oct4, Sox2 and Klf4. MEFs were transduced with 
reprogramming enhancers, Nr5a2 or Nr1i2 in combinations of SKM, OKM and OSM, 
to test for the enhancers’ ability to replace either Oct4, Sox2 or Klf4, respectively. 
Controls were MEFs transduced with only OKM, OSM or SKM. Data represent mean 
± SEM of three independent transduction experiment (n=3).  
 
 
These GFP-positive iPSC colonies created with the transduction of MEFs with Nr5a2 
and SKM are henceforth called N2SKM iPSCs (Figure 14A-B). The N2SKM iPSC 
colonies were further characterised for their similarities to mouse ESCs. Similar to 
mouse ESCs, these Nr5a2-reprogrammed cells stained positive for AP (Figure 14C), 
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express Nanog (Figure 14D-E), as well as the pluripotency-associated cell surface 
marker, SSEA1 (Figure 14F-G). 
 
     
Figure 14. Characterization of N2SKM iPSCs. (A) Phase contrast image of N2SKM 
iPSC colonies. (B) Fluorescence image of Pou5f1-EGFP-positive N2SKM iPSC 
colonies shown in (A). (C) Bright field image of AP-positive N2SKM iPSC colonies. 
(D) N2SKM iPSCs stain positive for Nanog. (E) Nuclei of N2SKM iPSCs in (D) are 
counterstained with Hoechst dye. (F) N2SKM iPSCs stain positive for cell surface 
marker, SSEA-1. (G) (E) Nuclei of N2SKM iPSCs in (G) are counterstained with 
Hoechst dye. Scale bars represent 200 µm in (A)-(C) and 50 µM in (D)-(G). 
 
 
As c-Myc is dispensable for reprogramming
55,66
, I tried to generate Nr5a2-
reprogrammed cells in the absence of both Oct4 and c-Myc. As expected, MEFs 
transduced with Nr5a2, Sox2 and Klf4 generated GFP-positive iPSCs (Figure 15), 
albeit at a much lower efficiency than when c-Myc is introduced (2.3 ± 0.6 iPSC 
colonies per 100,000 MEFs plated).  
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Figure 15. Reprogramming assay to investigate the ability of Oct4-replacer, 
Nr5a2 in its ability to reprogram in the absence of c-Myc. MEFs were transduced 
with Nr5a2 in addition to SK retroviruses, but in the absence of c-Myc. Control 
represents MEFs transduced with only SK retroviruses. Data represent mean ± SEM 
of three independent transduction experiment (n=3).  
 
These GFP-positive colonies (Figure 16A-B) are called N2SK iPSCs and are similar 
to the ESCs as they stain positive for AP (Figure 16C), Nanog (Figure 16D-E) and 












   
Figure 16. Characterization of N2SK iPSCs. (A)Phase contrast image of iPSCs 
generated with the transduction of Pou5F1-EGFP MEFs with N2SK. (B) GFP-
positive iPSC colonies in (A) as viewed under a fluorescence microscope. (C) 
Brightfield image of N2SK iPSC colonies, which are AP-positive. (D) N2SK iPSC 
colonies are Nanog-positive. (E) Nuclei in (D) are counterstained with Hoechst. (F) 
N2SK iPSC colonies expressed SSEA-1 cell surface protein. (G) Nuclei in (G) are 
counterstained with Hoechst. Scale bars represent 200 µm in (A)-(C) and 50 µM in 
(D)-(G).  
 
Analysis of Nr5a2-reprogrammed cells (N2SKM and N2SK iPSCs) showed that the 
transduced factors had been provirally integrated into their genome and there was no 
accidental transduction of Oct4 retroviruses as well that could explain how they had 
been successfully reprogrammed apparently without exogenous Oct4 (Figure 17A). In 






















Figure 17. Genotyping and karyotyping of Nr5a2-reprogrammed cells. (A) To 
ensure there is no cross contamination of retroviruses, the genomic DNA of Nr5a2-
reprogrammed cells were assayed for proper integration of the correct transduced 
retroviruses. PCR was carried out with a pMX vector-specific primer and a gene-
specific primer. Genomic DNA of OSKM iPSCs which harbour all OSKM 
retroviruses but no Nr5a2 retrovirus was used as a control. ESCs and Pou5f1-EGFP 
MEFs were used as negative controls. Control PCR was peformed on a genomic 
stretch of the p21 gene. (B) Karyotyping analysis of Nr5a2-reprogrammed cells 
displays a normal karyotype. 
 
3.5 Nr5a2-reprogrammed cells fulfil pluripotent assays 
 
The quintessential characteristic of a pluripotent cell is its multilineage differentiation 
potential. To begin authenticating whether Nr5a2-reprogrammed iPSCs are genuinely 
pluripotent, I differentiated them into embryoid bodies (EBs), after which the iPSCs 
were found to differentiate into cell types that derive from each of the three fetal germ 
layers, marked by Gata4 (endoderm), -smooth muscle actin (mesoderm), and nestin 
(definitive ectoderm) (Figure 18A). When Nr5a2 iPSCs were transplanted into 
immunocompromised SCID mice, they formed teratomas, comprising tissues 
originating from the endoderm, ectoderm as well as the mesoderm (Figure 18B). 
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These results show that Nr5a2-reprogrammed cells may be differentiated into 




Figure 18. EB differentiation assay and teratoma formation assay of Nr5a2-
reprogrammed cells. (A) EBs were formed from N2SKM (#A5) and N2SK iPSC 
(#B3 and #B11) lines and in vitro differentiated. Immunostaining to verify the 
formation of endodermal cells (anti-Gata4), ectodermal cells (Nestin) and mesodermal 
cells (α-smooth muscle actin) was performed. Blue (Hoeschst-stained nuclei); red 
(positively-stained marker). (B) Teratomas formed from the injection of iPSCs into 
SCID mice were dissected out, sectioned and stained. Differentiated cells 
representative of the three major germ layers were imaged. Scale bars represent 100 
μm in (A) and 50 μm in (B). 
 
Given that Nr5a2-induced iPSCs appeared pluripotent ex vivo as they were competent 
to differentiate into the three fetal germ layers in experimental situations, I performed 
a direct test of their developmental potency in vivo to verify that they were indeed 
bona fide pluripotent stem cells that could successfully contribute to developing 
embryos. To this end, morula aggregation was performed. Nr5a2-reprogrammed cells 
were microinjected into 8-cell stage WT C57BL/6J and B6(Cg)-Tyr
c-2J
/J (B6 albino) 
embryos. E13.5 embryonic chimeras that were formed had GFP expression in the 
gonads hence showing that the Nr5a2-reprogrammed cells are capable of germline 
incorporation (Figure 19A-B). In addition, live-born chimeras were also generated 
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(Figure 19C). Most importantly, these live-born chimeras when mated with an albino 
mice were able to generate offspring displaying the agouti and black furcoat, 
indicative of germline contribution of the Nr5a2-reprogrammed cells (Figure 19D). A 
summary of the performed pluripotent assays is reflected in Table 7.  
     
Figure 19. Nr5a2-reprogrammed cells exhibit germline incorporation, germline 
contribution and give rise to chimeras.  (A) Brightfield image of a male gonad 
harvested from an E13.5 chimeric mice generated from #B3 N2SK iPSCs. (B) Male 
gonad as shown in (A) is GFP-positive and this indicates germline incorporation of 
the N2SK iPSCs. (C) Live-born adult chimeric mouse generated from the 
microinjection of B6(Cg)-Tyr
c-2J
/J embryos with #B11 N2SK-reprogrammed cells 
(F1, 129S2/SV x Pou5f1-EGFP background). (D) Live-born offsprings derived from 
the mating of a N2SK #B11 adult male chimeric mice with a female albino B6(Cg)-
Tyr
c-2J
/J mouse. Germline transmission of the N2SK iPSCs is represented by the 

















Table 7. Pluripotency assays of Nr5a2-reprogrammed cells. 
 
Lines #A5 (N2SKM) #B3 (N2SK) #B11 (N2SK) 
EB formation    
   EB differentiation to 
cells of three germ 
layers 
   
   Teratoma formation 
consisting of tissues 
from three germ 
layers 
   
   Gonad incorporation    
   Chimeras    
   Germline 
transmission 
- -  

Table Legend 
 denotes iPSC line passing the assay. 
-  no germline transmission was observed. 
 
3.6 Epigenetic and transcriptional profiles of Nr5a2-reprogrammed cells are 
akin to ESCs 
To test whether Nr5a2-reprogrammed cells are epigenetically akin to ESCs, I 
performed bisulphite sequencing of the Oct4 and Nanog promoters in Nr5a2-
reprogrammed cells to assess the CpG methylation status of these pluripotency-
associated regulatory regions. The Oct4 and Nanog promoter regions in the starting 
MEFs are largely methylated (Figure 20). However, akin to mouse ESCs, the Oct4 
and Nanog promoters of the Nr5a2 iPSCs were largely unmethyated (Figure 20), 
hence indicating that the Nr5a2 iPSCs were epigenetically similar to the former.  
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Moreover, the whole-genome transcriptional profiles of the Nr5a2 iPSCs were also 
characterised and compared to that of mouse ESCs. Microarray profiling was 
performed, and hierarchical clustering of the resultant datasets revealed that Nr5a2-
reprogrammed cells clustered closely with mouse ESCs whereas both Pou5f1-EGFP 
and actin-EGFP MEFs clustered with one other (Figure 21A). In addition, Nr5a2-
reprogrammed cells displayed an expression of ESC highly-expressed genes and a 
downregulation of MEF highly-expressed genes (Figure 21B), suggesting that they 






                                 
Figure 20. Promoter methylation profile of Nr5a2-reprogrammed cells. 
Bisulphite-treated genomic DNA was sequenced before promoter methylation status 
of Pou5f1 and Nanog promoter regions was determined. Methylation profile of 
Nr5a2-reprogrammed cells in addition to ESCs and MEFs were investigated. Ten 
different clones harbouring the amplified promoter regions were sequenced. Red dots 










                       
Figure 21. Transcriptome analysis of Nr5a2-reprogrammed cells. (A) Hierarchical 
clustering of Nr5a2-reprogrammed cells (#A5, #B3 and #B11) with MEFs (actin-
EGFP and Pou5f1-EGFP), ESCs and OSKM-reprogrammed iPSCs. Correlation 
analysis (46,643) was performed in the clustering analysis. (B) Heatmap depicting the 
expression profile of Nr5a2-reprogrammed cells with MEFs, ESCs and OSKM-
reprogrammed iPSCs. Expression profile of 1000 mouse ESC-associated and MEF-
associated genes were selected. Genes were chosen based on fold differences of gene 
expression in ESCs and Pou5f1-EGFP MEFs, sorted by average expression ratio, and 
mean-centered to the Pou5f1-EGFP MEF signal. Red represents upregulation of gene 
expression whereas green represents downregulation of gene expression with respect 










3.7 The other nuclear receptors are unable to replace exogenous Oct4 in 
reprogramming 
To investigate if the Oct4-replacing capability of Nr5a2 is unique to this nuclear 
receptor, I investigated the other nuclear receptors in my screen for their potential to 
also replace Oct4. However, Nr5a2 was the only nuclear receptor capable of replacing 
exogenous Oct4 in the generation of mouse iPSCs (Figure 22), suggesting that Oct4 









Figure 22. Reprogramming assay to test for the ability of the other nuclear 
receptors in substituting for Oct4. The rest of the 17 nuclear receptors were tested 
for their ability to replace Oct4, and Nr5a2 was used as a positive control. Control 
represents MEFs transduced with only SKM retroviruses. Data represent mean ± SEM 
of three independent transduction experiment (n=3).  
 
 
3.8 Nr5a1, the close family member of Nr5a2 possesses similar reprogramming 
capabilities as its counterpart 
Close family members of reprogramming factors have been shown to be able to 
replace their counterparts in reprogramming, albeit at varying efficiencies. For 
instance, L-Myc and N-Myc have been shown to be able to replace c-Myc, In 
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addition, Klf1, Klf2 and Klf5 can substitute for Klf4, and Sox2 can be replaced by 
Sox1 and Sox3
55
. Furthermore, Esrrg, the close relative of the nuclear receptor Esrrb, 
can also replace the latter in the substitution of exogenous Klf4 in murine 
reprogramming
85
. To this end, I investigated if Nr5a1, the close family member of 
Nr5a2 for its potential in recapitulating Nr5a2’s ability to enhance reprogramming and 
substitute for exogenous Oct4.  
Interestingly, Nr5a1 was also able to enhance reprogramming efficiency, albeit at a 
lower efficiency (Figure 23A). Similar to Nr5a2, Nr5a1 was unable to replace 
exogenous Sox2 and Klf4 but was able to substitute for exogenous Oct4 in 
reprogramming, but at an otherwise lower efficiency (Figure 23B). 
 
Figure 23. Reprogramming assay to test enhancement and canonical factors-
replacement capabilities of Nr5a1. (A) Reprogramming assay to test the ability of 
Nr5a1 in enhancing reprogramming, similar to Nr5a2. Control is MEFs transduced 
with only OSKM. (B) Reprogramming assay to test the ability of Nr5a1 in replacing 
Oct4, Sox2 or Klf4 in reprogramming. Control is MEFs transduced with only OKM, 
OSM or SKM. Data represents mean ± s.e.m. of three retrovirus-mediated 
transduction experiments (n=3). 
 
These Pou5f1-EGFP-positive Nr5a1-reprogrammed cells (Figure 24A-B) are referred 
to as N1SKM iPSCs and similar to mouse ESCs, they stain positive for AP (Figure 




             
Figure 24. Characterization of Nr5a1 iPSCs. (A)Phase contrast image of iPSCs 
generated with the transduction of Pou5F1-EGFP MEFs with N1SKM. (B) GFP-
positive iPSC colonies in (A) as viewed under a fluorescence microscope. (C) 
Brightfield image of N1SKM iPSC colonies, which are AP-positive. (D) N1SKM 
iPSC colonies are Nanog-positive. (E) Nuclei in (D) are counterstained with Hoechst. 
(F) N1SKM iPSC colonies expressed SSEA-1 cell surface protein. (G) Nuclei in (G) 
are counterstained with Hoechst. Scale bars represent 200 µm in (A)-(C) and 50 µM 
in (D)-(G).  
 
Genomic PCR was performed to confirm that these N1SKM iPSCs were not created 
from any cross-contamination of Nr5a2 and Oct4 retroviruses (Figure 25A). In 
addition, N1SKM iPSCs displayed normal karyotypes (Figure 25B).  
 
                  
Figure 25. Genotyping and karyotyping of Nr5a1-reprogrammed cells. (A) To 
ensure there is no cross contamination of Nr5a2 or Oct4 retroviruses, the genomic 
DNA of Nr5a1-reprogrammed cells were assayed for integration of the Nr5a1 
retroviruses and not that of Nr5a2 or Oct4. PCR was carried out with a pMX vector-
specific primer and a gene-specific primer. Genomic DNA of OSKM iPSCs which 
harbour all the Oct4 retroviruses but no Nr5a2 and Nr5a1 retrovirus was used as a 
control. ESCs were used as negative controls. Control PCR was peformed on a 
genomic stretch of the p21 gene. (B) Karyotyping analysis of Nr5a1-reprogrammed 
cells displays a normal karyotype. 
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In addition, Nr5a1-reprogrammed cells were able to differentiate to cells and tissues 
originating from all three major germ layers as evidenced by the EB-mediated 
differentiated assay (Figure 26A) and teratoma formation assay (Figure 26B). These 
results therefore indicate the pluripotent capabilities of the Nr5a1-reprogrammed 
cells. 
 
              
Figure 26. EB differentiation assay and teratoma formation assay of Nr5a1-
reprogrammed cells. (A) EBs were formed from N1SKM iPSC lines and in vitro 
differentiated. Immunostaining to verify the formation of endodermal cells (anti-
Gata4), ectodermal cells (Nestin) and mesodermal cells (α-smooth muscle actin) was 
performed. Blue (Hoeschst-stained nuclei); red (positively-stained marker). (B) 
Teratomas formed from the injection of N1SKM iPSCs into SCID mice were 
dissected out, sectioned and stained. Differentiated cells representative of the three 
major germ layers were imaged. Scale bars represent 100 μm in (A) and 50 μm in (B). 
 
Furthermore, akin to mouse ESCs, Nr5a1-reprogrammed cells had Oct4 and Nanog 
promoter methylation profiles largely unmethylated (Figure 27), hence demonstrating 
the successful epigenetic reprogramming of the MEFs at the genomic level. 
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Figure 27. Promoter methylation profile of Nr5a1-reprogrammed cells. 
Bisulphite-treated genomic DNA was sequenced before promoter methylation status 
of Pou5f1 and Nanog promoter regions were determined. Methylation profile of 
Nr5a2-reprogrammed cells in addition to ESCs and MEFs were investigated. Ten 
different clones harbouring the amplified promoter regions were sequenced. Red dots 
represent methylated cytosines whereas white dots represent unmethylated cytosines.  
 
3.9 Other transcription factors that bind to Oct4 regulatory region are unable to 
replace exogenous Oct4 in reprogramming 
Nr5a2 has been previously shown to bind to the Pou5f1 proximal enhancer and 
proximal promoter in mouse epiblast cells during early development
166
. In addition, 
mouse epiblast devoid of Nr5a2 tends to exhibit a loss of Oct4 expression
166
. Hence, it 
is plausible that part of the mechanism behind Nr5a2’s ability to replace exogenous 
Oct4 in reprogramming is its direct activation of Oct4. 
To investigate if other transcription factors that bind to Pou5f1 regulatory elements
176
 
can also replace exogenous Oct4 in the generation of mouse iPSCs, I assayed 9 other 
transcription factors (Nanog, Sall4, Stat3, Zfx, Tcfcp2l1, Klf2, Klf5, N-Myc and 
Esrrb), which have been shown to bind to Oct4 regulatory elements in mouse ESCs, 
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for their ability to substitute for Oct4 in reprogramming. However, none of these 
Oct4-binders in mouse ESCs were able to replace exogenous Oct4 in reprogramming, 











Figure 28. Investigation if other transcription factors that bind to Oct4 
regulatory regions could also substitute for Oct4 in reprogramming. (A) Gene 
transcripts of expression from pMX vector harbouring the genes of other transcription 
factors (Nanog, Sall4, Stat3, Zfx, Tcfcp2l1, Klf2, Klf5, N-Myc, Esrrb) that also bind 
to Pou5f1 regulatory regions. PCR was performed on cDNA with a pMX vector-
specific primer and a gene-specific primer. (B) Reprogramming assay of the ability of 
other transcription factors that bind to Oct4 regulatory regions to substitute for 
exogenous Oct4 in reprogramming. Nr5a1 and Nr5a2 were used as positive controls. 
Control represents MEFs transduced with only SKM retroviruses. Data represents 
mean ± s.e.m. of three retrovirus-mediated transduction experiments (n=3). 
 
3.10 Nr5a2 sumoylation mutants can further enhance the efficiency of 
reprogramming 
It has been shown that the mutation of specific lysine residues of Nr5a2 that can 
otherwise be conjugated to SUMOs will result in Nr5a2 exhibiting an enhanced 
transcriptional activity and a reduced localisation into inactive nuclear bodies
169
. The 
2KR mutant has two important lysine residues mutated to arginine while the 5KR 
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mutant has five important lysine residues mutated to arginine
169
 (Figure 29). To 
investigate if these sumoylation mutants of Nr5a2 can also enhance murine 
reprogramming, I utilised 2KR and 5KR Nr5a2 mutants to test for their potential in 
further enhancing the efficiency of reprogramming as compared to WT Nr5a2.  
                             
 
 
Figure 29. Schematic diagram of 2KR and 5KR sumoylation mutants of Nr5a2. 
Important lysine residues when mutated, would prevent its conjugation with a SUMO 
molecule. Nr5a2 2KR mutant has two lysine residues mutated (lysine 173 and 289), 
whereas Nr5a2 5KR mutant has five lysine residues mutated (lysine 173, 213, 289, 
329, 389). 
 
Western blot analysis confirmed the equal expression of Nr5a2 protein from the WT 
Nr5a2, Nr5a2 2KR, as well as the Nr5a2 5KR pMX constructs (Figure 30A). From 
the OSKM reprogramming assay, it was observed that when Nr5a2 2KR mutant was 
used in place of WT Nr5a2, an almost 8-fold enhancement of reprogramming 
efficiency (as compared to 4-fold with WT Nr5a2) was achieved (Figure 30B). A 
greater reprogramming efficiency of almost 12-fold was achieved when the Nr5a2 
5KR mutant was utilised (Figure 30B). In addition, a similar pattern of enhancement 
of efficiency was observed in the replacement of Oct4 with Nr5a2. There was a 
progressive increase in the number of N2SKM colonies when WT Nr5a2 is substituted 
with Nr5a2 2KR and in turn with Nr5a2 5KR (Figure 30C). These results show that 
sumoylation mutants of Nr5a2 can indeed enhance reprogramming efficiency and this 
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is most likely due to its ability to exert enhanced transcriptional activity and reduced 





















Figure 30. Investigation of sumoylation mutants of Nr5a2 in their ability to 
enhance reprogramming. (A) Western analysis of protein expression of Nr5a2 
sumoylation mutants (2KR and 5KR) from pMX vector. 293-T cells were transfected 
with pMX vectors harbouring the Nr5a2 sumoylation mutant genes. (B) 
Reprogramming assay to test the ability of the Nr5a2 sumoylation mutants in 
enhancing OSKM reprogramming efficiency. Control represents MEFs transduced 
with only OSKM retroviruses. (C) Reprogramming assay to test the ability of the 
Nr5a2 sumoylation mutants in enhancing N2SKM reprogramming efficiency. Data 






3.11 Genome wide binding analysis of Nr5a2 in mouse ESCs reveals that it 
shares many common target genes as its reprogramming counterparts, Sox2 and 
Klf4 
By investigating genome-wide, the targets of Nr5a2 in mouse ESCs, the intricate 
mechanism of Nr5a2 in mediating the enhancement of reprogramming and the 
replacement of exogenous Oct4 could in part be deciphered. A stable mouse ESC line 
expressing HA-tagged Nr5a2 was created. Western blot analysis shows that HA-
tagged Nr5a2 protein was expressed at an approximately equivalent amount as 
endogenous Nr5a2 (Figure 31A).  Chromatin immunoprecipitation coupled to 
sequencing (ChIP-seq) was performed on Nr5a2 (HA-tagged) using a HA-specific 
antibody. MEME, a de novo motif discovery algorithm, which searches for over-
represented sequences, uncovered a known Nr5a2 motif enriched in the dataset 
(Figure 31B). Pairwise co-occurrence analyses show that Nr5a2 tends to co-localise 
with important ESC transcription factors such as Oct4, Sox2 and Nanog (Figure 31C). 
Nr5a2 also co-localises with other factors, Esrrb and Tbx3 that were also found to 
play a role in reprogramming
85,177
 (Figure 31C). On the other hand, c-Myc, Zfx and 
N-Myc were clustered in another cluster as also evidenced in another study
176
. In 
addition, Nr5a2 and its reprogramming counterparts of Sox2 and Klf4 share many 
common target genes pivotal for ESC maintenance such as Oct4 and Nanog, and 









Figure 31. Genome wide mapping of Nr5a2 binding sites. (A) Western blot 
analysis of endogenous Nr5a2 and 3HA-Nr5a2 protein expression from Nr5a2 3HA-
tagged stable cell line. Lane 1 represents Nr5a2 protein bands from ESC sample, 
while lane 2 represents Nr5a2 protein bands from stable cell line. Upper band in lane 
2 denotes 3HA-tagged Nr5a2 protein and the lower band denotes endogenous Nr5a2 
protein. (B) Sequence of Nr5a2 binding motif generated by the de novo motif 
discovery algorithm, MEME. (C) Heat map showing the co-occurrence of Nr5a2 with 
other ESC-relevant transcription factors. Each individual square represents the 
colocalisation frequency of two different transcription factors. Yellow denotes a 
greater colocalisation frequency whereas orange denotes a lower colocalisation 
frequency. Transcription factors within the blue box tend to colocalise with Nr5a2 
whereas those within the black box belong to the Myc cluster. (D) Genes bound by 
Nr5a2 in addition to Sox2 and Klf4 play important roles in maintaining ESC identity 
and promoting cell proliferation. (E) Binding profiles of the transcription factors, 
Nr5a2, Sox2 and Klf4 to the same target genes.  
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3.12 Nr5a2 works in part through Nanog in reprogramming 
Nanog is one of the transcriptional targets of Nr5a2 in mouse ESCs (Figure 31D-E) 
and I was interested to further explore this downstream target of Nr5a2 in the context 
of murine reprogramming. ChIP experiment demonstrated that Nr5a2 is bound to the 








Figure 32. ChIP assay to investigate the binding of Nr5a2 to the Nanog enhancer 
during the reprogramming of MEFs. ChIP assay was carried out on 8 dpi HA-
Nr5a2+OSKM-infected MEFs. Quantitative real-time PCR was performed to 
investigate the enrichment of HA-Nr5a2 on the Nanog enhancer. 
 
In addition, time-course expression studies reveal that Nanog is gradually upregulated 
by up to 2-fold during reprogramming when Nr5a2 is introduced to OSKM as 
compared to OSKM alone (Figure 33). This expression of Nanog is upregulated in a 
similar fashion as endogenous Oct4 is when Nr5a2 is added into the reprogramming 
cocktail (Figure 33B-C). These results suggest that Nr5a2 works in part through 





        
Figure 33. Upregulation of Nanog during reprogrammig with Nr5a2 (A) Gene 
expression fold change of Nanog in OSKM+Nr5a2 cells during reprogramming as 
compared to OSKM. Time-course microarray data at 3, 7 and 11 dpi was performed 
and data is derived from biological triplicates. Fold change in expression levels of 
ESC-relevant genes, Gdf3 and Zic3 are also reflected on the graph for comparison 
with Nanog. (B) Time-course fold change of endogenous Pou5f1 mRNA level during 
reprogramming in OSKM+Nr5a2 and OSKM-infected MEFs with respect to 
uninfected MEFs. (C) Time-course fold change of endogenous Nanog mRNA level 
during reprogramming in OSKM+Nr5a2 and OSKM-infected MEFs with respect to 
uninfected MEFs. Real-time quantitative PCR was carried out on biological triplicate 
samples in both (C) and (D). 
 
I decided to explore further the downstream target of Nanog in reprogramming. I 
created a knockdown construct of Nr5a2 and cloned it into the pMX retroviral 
plasmid. The pMX retroviral plasmid harbouring the Nr5a2 knockdown construct was 
transfected into mouse ESCs, and successfully transfected cells were selected for with 
the puromycin antibiotic. This knockdown construct was able to reduce the transcript 
levels of Nr5a2 by about 80% (Figure 34A) as well as reduce Nr5a2 protein 
expression when introduced into mouse ESCs (Figure 34B). 
  
Figure 34. Gene and protein expression of Nr5a2 after shRNA-mediated 
knockdown. (A) Quantitative real time PCR was performed to determine the relative 
gene transcript level of Nr5a2 after Nr5a2 shRNA-mediated knockdown in mouse 
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ESCs. Control represents mouse ESCs knockdown with a construct harbouring the 
RNAi sequence of the luciferase gene. Data represents mean ± s.e.m. of three 
retrovirus-mediated transduction experiments (n=3). (B) Western analysis to 
determine the protein expression of Nr5a2 after Nr5a2 shRNA-mediated knockdown 
in mouse ESCs. Control represents ESCs knockdown with a construct harbouring the 
RNAi sequence of the luciferase gene. Protein expression of the house keeping gene, 
actin is used as a control.  
 
MEFs were transduced with this knockdown construct of Nr5a2 in addition to 
OSKM. When Nr5a2 knockdown construct is introduced during reprogramming, 
there was about a 2-fold reduction in the number of generated iPSC colonies (Figure 
35). However, when Nanog is co-transduced with the knockdown of Nr5a2, there is 
an increase in the number of iPSC colonies (Figure 35), thus showing that Nanog can 
rescue the knockdown effects of Nr5a2 during reprogramming. On the other hand, an 
independent factor, Mtf2, which was previously not associated with conferring 
pluripotency and self-renewal, was unable to rescue the knockdown effects of Nr5a2 
during reprogramming (Figure 35). The knockdown of Pou5f1 during reprogramming 
generated almost no colonies and even the introduction of Nanog could not rescue the 
effects of Pou5f1 knockdown during reprogramming (Figure 35). These results 








Figure 35. Knockdown of Nr5a2 during reprogramming. MEFs were infected with 
retroviruses harbouring Nr5a2 RNAi in addition to OSKM retroviruses. Control 
represents MEFs infected with only OSKM retroviruses. Control RNAi represents 
RNAi for the luciferase gene and was used as a negative knockdown control. Pou5f1 
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RNAi during reprogramming was performed as a positive control. Rescue of the 
reduction of the number of colonies was attempted with transduction of Nanog or 
Mtf2 retroviruses. Data represents mean ± s.e.m. of three retrovirus-mediated 
transduction experiments (n=3). 
 
Nanog itself could not significantly increase the number of colonies when introduced 
with OSKM unlike Nr5a2 (Figure 36). However, when both Nr5a2 and Nanog were 
co-introduced with OSKM, there is a further increment in the number of iPSC 
colonies generated (Figure 36), this suggests a plausible synergistic effect of both 
Nr5a2 and Nanog in reprogramming. 
 
                              
Figure 36. Reprogramming assay with combined transduction of Nr5a2 and 
Nanog in the presence of OSKM. Control represents MEFs transduced with only 
OSKM retroviruses. Data represents mean ± s.e.m. of three retrovirus-mediated 
transduction experiments (n=3). 
 
3.13 Nr5a2 works in a p53-pathway inhibition-independent fashion 
          
Several groups have conclusively shown that the inhibition of the p53-p21 pathway 
could enhance the generation of iPSCs
133-137
. In this respect, I wanted to investigate if 
the enhancement of reprogramming by Nr5a2 works via inhibition of the p53 pathway 
besides its Nanog effect. Analysing the data of Nr5a2 knockdown in mouse ESCs, I 
found that p53 and p21 transcript expression levels were largely unaffected after 
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Nr5a2 knockdown. (Figure 37). In addition, neither p53 nor p21 are directly bound by 
Nr5a2 in mouse ESCs (data not shown). 
 
                                
Figure 37. Heatmap depicting p53 and p21 expression after Nr5a2 knockdown. 
p53 and p21 expression is not largely affected after knockdown of Nr5a2 in mouse 
ESCs. Control is the knockdown of luciferase, a non-existent gene in mouse ESCs 
and gene expression in Nr5a2 knockdown cells are normalised to the expression in 
the luciferase knockdown cells. Expression of Nr5a2 is included in the heatmap to 
show its successful knockdown. Red represents upregulation and green represents 
downregulation. Data is derived from biological triplicates. 
 
Nonetheless, I decided to implement a direct experimental test to investigate if Nr5a2 
indeed represses the p53 pathway to enhance reprogramming. To this end, I 
reprogrammed p53-null MEFs with Nr5a2 in combination with OSKM and compared 
them with OSKM-reprogrammed WT MEFs. I also compared the results with the 
reprogramming of p53-heterozygous (het) and p53-WT MEFs. Quantitation of AP-
positive colonies instead of Pou5f1-EGFP-positive colonies was performed as these 
cells do not harbour the Pou5f1-EGFP reporter (Figure 38A). Similar to what was 
previously reported, there is a progressive enhancement in the number of AP-positive 
iPSC colonies from p53-WT to p53-het and then to p53-null (Figure 38A-B). Even 
when Nr5a2 was introduced to OSKM during reprogramming, there was also a 
similar progressive enhancement in the number of AP-positive iPSC colonies from 
the p53-WT to the p53-null background. However, there was no marked augmentation 
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of AP-positive colonies when Nr5a2 was introduced to a p53-null background (Figure 
38A-B). This suggests that Nr5a2 works independent of inhibition of the p53 pathway 
to enhance reprogramming. 
 
             
Figure 38. Reprogramming of p53 WT, Het and KO MEFs in the presence of 
Nr5a2. (A) AP-staining of p53 WT, p53, Het and p53 KO MEFs reprogrammed with 
OSKM or OSKMN (with Nr5a2). (B) Quantitation of AP-positive iPSC colonies at 14 




3.14 Nr5a2 does not enhance or replace exogenous Oct4 in human 
reprogramming 
Next, I wanted to investigate if Nr5a2 also enhances and replaces exogenous OCT4 in 
the reprogramming of human cells. Human iPSC generation is indeed challenging in 
that it remains technically painstaking to isolate successfully-reprogrammed iPSCs; 
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although a variety of complex approaches of varying success have been approached, 
the main criteria still remains staining for AP-positive human iPSC colonies or 
selecting successfully-reprogrammed human iPSC colonies based on morphological 
likeliness to human ESCs alone. Both current approaches are highly inaccurate—
partially-reprogrammed human iPSCs invariantly exhibit AP expression (AP is 
upregulated at an early stage in reprogramming) and have hESC-like morphology. 
This is contradistinct to the scenario in the mouse iPSC reprogramming field, wherein 
the ease of transgenic modification in the mouse has yielded a veritable arsenal of 
reporter transgenes (e.g., Oct4-Gfp, Nanog-Gfp, and Sox2-Gfp) that allow for precise 
and experimentally facile identification of successfully-reprogrammed mouse iPSC 
colonies.  
To recreate the transgenic reporter tools that we have in the mouse into the human 
background, I created a POU5F1-EGFP human ESC line. A bacterial artificial 
chromosome (BAC) harbouring the POU5F1 gene was modified to contain an EGFP-
pA-FRT-PGK-neo-FRT cassette at the POU5F1 start codon (ATG) (Figure 39A). 
This cassette essentially introduces the EGFP gene in place of the POU5F1 gene as 
well as inserts an antibiotic-resistant marker for selection of cells successfully 
integrated with this cassette. The modified BAC construct was then linearised to 
possess a 73.3 kb long arm and a 16.0 kb short arm, and then electroporated into H1 
human ESCs. Thereafter, the reporter transgene was introduced into one copy of the 
endogenous POU5F1 locus via homologous recombination in successful 
transfectants. POU5F1 is highly expressed in human ESCs, and hence one would 
expect that successfully-targeted POU5F1
+/GFP
 human ESCs would be GFP-positive 
and also manifest neomycin resistance. GFP-positive human ESC colonies were 
picked (Figure 39B) and assayed for correct integration of the cassette into the 
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POU5F1 locus via long range PCR (Figure 39C) and Southern blot (Figure 39D). 
These POU5F1-EGFP human ESCs displayed a normal karyotype (Figure 39E) and 
GFP expression could be extinguished upon retinoic acid-induced differentiation, 
suggesting that here, POU5F1-EGFP reporter activity correlates well with known 
endogenous POU5F1 expression (Figure 39F).  
These human ESCs were then allowed to differentiate into fibroblasts in regular 
fibroblast media (10% FBS-supplemented DMEM media) and passaged for 4 
passages to obtain a homogenous culture of human fibroblasts (Figure 40). In 
addition, no GFP-positive cells were observed and this indicates that all the 
undifferentiated human ESCs have been differentiated (Figure 40). Two weeks after 
transduction of these POU5F1-EGFP human fibroblasts with OSKM retroviruses and 
after about 2 weeks of infection, GFP-positive human iPSC colonies could be 
observed (Figure 39), demonstrating that this POU5F1-EGFP endogenous reporter I 
have engineered enables the facile detection  of successfully-reprogrammed human 
iPSCs.   
I then performed a reprogramming assay to test if human NR5A2 could potentiate the 
reprogramming of human cells to iPSC. However, strikingly, unlike what I saw in the 
mouse, in human cells, NR5A2 was not only unable to enhance reprogramming 
efficiency, but it actually also slightly reduced it (Figure 41A). In addition, NR5A2 
was unable to replace exogenous OCT4 in human reprogramming (Figure 41), unlike 
in murine reprogramming. All in all, these results show that Nr5a2 most likely has 







Figure 39. Creation of POU5F1-EGFP human ESC line. (A) Targeted insertion of 
the EGFP-pA-FRT PGK-neo FRT cassette in front of the POU5F1 start codon via 
homologous recombination with a linearised construct modified from BAC DNA with 
a 73.3 kb long arm and a 16.0 kb short arm. (B) Green fluorescence of a successfully 
targeted human ESC line. Untargeted H1 human ESCs do not display green 
fluorescence. (C) Long-range PCR to verify the insertion of the cassette into the right 
locus detects a 16.3 kb sequence. Forward and reverse primers used are reflected as 
blue arrows in the schematic diagram in (A). (E) Normal karyotype of the POU5F1-
EGFP human ESC line. (F) RA-treatment differentiates the POU5F1-EGFP human 
ESC line and GFP expression becomes extinguished. Scale bars in (B) and (F) 




                        .  
Figure 40. Reprogramming of POU5F1-EGFP human fibroblasts. Human OSKM 
retroviruses were used to infect POU5F1-EGFP human fibroblasts. POU5F1-EGFP-
positive human iPSC colonies were derived after 14 days. Uninfected fibroblasts do 




            
Figure 41. Assay to test if NR5A2 can enhance or replace OCT4 in human 
reprogramming. (A) Enhancement assay for NR5A2 in human reprogramming. 
Control represents POU5F1-EGFP human fibroblasts that were transduced with only 
OSKM. (B) OCT4 replacement assay for NR5A2 in human reprogramming. OSKM is 
a positive control whereas SKM (control) is a negative control. Data represents mean 









4.1 The identification of more nuclear receptor factors associated with 
reprogramming 
Prior to the findings of this study, only one nuclear receptor, Esrrb, was implicated in 
the reprogramming of somatic cells to iPSCs
85
. The study by Feng et al found that 
Esrrb was able to replace exogenous Klf4 in the reprogramming of mouse fibroblasts. 
Compelled by the impetus to enhance the otherwise inefficient process of 
reprogramming and to also search for more nuclear receptors that participate in 
reprogramming, I embarked on a screen of nuclear receptors in search for more 
enhancers of iPSC generation
86
.  
Here, I have reported the discovery of several other nuclear receptors that can also 
participate in the reprogramming process. From a screen of 19 nuclear receptors 
(Table 6), I found nuclear receptors, Nr1i2 and Nr5a2 to be able to enhance 
reprogramming by about 2- fold and 4-fold respectively (Figure 10). Similarly, Nr5a1, 
the close family member of Nr5a2, is also able to enhance reprogramming, albeit at a 
slightly lower extent of about 3-fold (Figure 23). After the findings of this study were 
published, another group corroborated my findings and reported that Nr5a2, in 
addition to another factor, can enhance the efficiency of murine reprogramming
178
. 
The identification of 3 nuclear receptors (Nr1i2, Nr5a1 and Nr5a2) that can augment 
the efficiency of reprogramming adds to the increasing repertoire of factors that can 
positively contribute to the reprogramming process. In addition, this discovery 
expands our knowledge on the ability of a specialised superfamily of proteins - the 
nuclear receptors, in their abilities to promote reprogramming. 
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Amongst the 3 reprogramming enhancers reported herein this study, only Nr5a2 is 
expressed in mouse ESCs
166
, similar to Esrrb. It is not surprising that factors 
expressed in mouse ESCs can contribute to the moulding of somatic cells back to the 
pluripotent and self-renewing state. Hence, it is interesting that even factors that are 
not expressed in mouse ESC such as Nr1i2 and Nr5a1 can enhance the 
reprogramming process. Nr1i2 is highly expressed in the liver and intestines
179
, 
whereas Nr5a1 is highly expressed in the adrenal cortex as well as Leydig, Sertoli 
cells
180
. Nonetheless, this is not the first instance of factors that are not expressed in 
ESCs that can augment the efficiency of reprogramming. SV40 large T antigen, a 
factor used in cell transformation and isolated from the SV40 polyomavirus has been 
implicated in the enhancement of human reprogramming
50,138
. On the other hand, the 
removal of certain factors such as that of tumour suppressor, p53 can also contribute 
to an augmentation of reprogramming efficiency
158
. Hence, it is somewhat not 
surprising that factors not within the ESC transcriptional mileau can also contribute to 
the improvement of the generation of iPSCs. 
 
4.2. Nr5a2, the first factor reported that can replace exogenous Oct4 in 
reprogramming 
Remarkably, besides, being able to enhance reprogramming efficiency, Nr5a2 was 
found to be able to replace exogenous Oct4 in the reprogramming of mouse 
fibroblasts
86
. Prior to the findings of this study, no factor has been reported to be able 
to replace exogenous Oct4 in reprogramming. Hence, this finding reports for the first 
time a novel factor that can substitute for Oct4 in the generation of iPSCs.  
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The replacement of Oct4 in reprogramming is remarkable as amongst the four 
transcription factors, Oct4 is arguably the most important factor for reprogramming. 
First, not long after the method of reprogramming with the four transcription factors 
was discovered, c-Myc was shown to be dispensable for reprogramming
55,66
. Sox2 
and Klf4 were then found to be dispensable for reprogramming as alternative 
transcription factors and even chemical compounds have been found to replace both 
Sox2 and Klf4 in the reprogramming of mouse and human cells. A chemical screen 
for the substitution of Sox2 in murine reprogramming has been performed, and 
inhibitors of Tgf-β receptors were found to be able to replace Sox257. Another 
independent study also demonstrated the replacement of Sox2 (and c-Myc) with the 
inhibition of the Tgf-β signalling pathway181. Moreover, Tgf- receptor inhibitors, 
chemical inhibitors of GSK3 and lysine-specific demethylase 1 (Lsd1) have been 
shown to together replace Sox2 in human reprogramming
182
. Similarly, a chemical 
screen to replace Klf4 was also carried out and a chemical known as kenpaullone was 
discovered to replace Klf4 in the generation of mouse iPSCs
62
. In addition, our group 
had shown that Klf4 could be substituted for by Esrrb in the reprogramming of 
MEFs
85
. Even neural stem cells, which express a high level of endogenous Sox2, 
solely require exogenous Oct4 to be reprogrammed into iPSCs
95,96
. Furthermore, no 
transcription factor, let alone a cellular factor has been shown to be able to replace 
Oct4 in reprogramming. Even Oct1 and Oct6, close family members of Oct4, are 
unable to replace Oct4 in reprogramming
55
. Indeed, current arsenals of chemical 
compounds developed to eventually achieve solely “chemical reprogramming” still 
fail to replace Oct4 with chemical compounds; mouse fibroblasts now can be 
reprogrammed with solely a TGF- receptor inhibitor and a chemical PRMT inhibitor 
in addition to Oct4 transduction
183
 and moreover, human fibroblasts may be 
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reprogrammed with Oct4 transduction in combination with contemporaneous 
treatment with four chemical compounds (a TGF- receptor inhibitor, a MAPK/ERK 
receptor inhibitor, an HDAC inhibitor, and a PDK1 activator)
184
. Thence, it seems that 
the requirement for Oct4 in reprogramming is figuratively speaking the last 
metaphorical stronghold to be conquered in terms of factor replacement that has 
withstood replacement with chemical compounds or alternative transcription 
factors—until my study. These additively demonstrate the criticality of Oct4 in 
reprogramming and to find a factor in Nr5a2 to be able to replace an important factor 
like Oct4 in reprogramming is indeed spectacular.  
Intriguingly, after the findings of this study, there was a study which reported the 
complete reprogramming of both mouse and human somatic cells with only 
microRNAs from the miR-302-367 family
152
. No other exogenous factors such as 
Oct4 were required. Nonetheless, there was no direct demonstration of a one-on-one 
substitution of exogenous Oct4, and the combination of microRNAs probably works 
synergistically to mediate reprogramming on a whole.  
 
4.3 The parallel importance of Nr5a2 in mouse ESCs, early embryogenesis and 
reprogramming 
My study discloses a potent role for Nr5a2 in the instatement of pluripotency—not 
only does exogenous expression of Nr5a2 functionally replace Oct4, but moreover, 
knockdown of endogenous Nr5a2 in reprogramming cells also aborts iPSC 
generation. My findings are supported by a wealth of previous findings that Nr5a2 has 
an imperative role in early embryonic development and in vivo within the pluripotent 
cells of the epiblast. Genetic deletion of Nr5a2 leads to extremely early embryonic 
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lethality at E6.5-E7.5 shortly after implantation
185
. These embryonic lethal Nr5a2-null 
embryos exhibit growth abnormalities, improper organisation of the epiblast layer as 
well as embryonic-extraembryonic constriction
186
. Moreover, these abnormal embryos 
display retarded primitive streak formation, hence showing that Nr5a2 is important for 
proper primitive streak morphogenesis
186
.  In the normal embryo, Nr5a2 is shown to 
colocalise with Oct4 in both the ICM and the epiblast of the early mouse embryo. 
However, in Nr5a2-null mouse embryos, Oct4 expression is not maintained in the 
epiblast
166
. In addition, Nr5a2-null mouse ESCs, tend to differentiate more easily and 
have its Oct4 expression reduced more quickly as compared to WT ESCs when 
subjected to RA-induced differentiation
166
. 
Taken together, the importance of Nr5a2 in mouse ESCs as well as early mouse 
embryogenesis indeed mirrors the importance of Nr5a2 in reprogramming of somatic 
cells to a pluripotent state. This also brings into perspective of how better studying the 
intrinsic maintenance of mouse ESC pluripotency can allow us to better unravel the 
complex mechanisms underlying reprogramming and also vice versa. 
 
4.4 Nr5a2 works in part through Nanog to mediate reprogramming 
Nr5a2 is known to bind to both the proximal enhancer and proximal promoter of 
Pou5f1, hence promoting its expression in the epiblast stage of murine 
development
166
. Prior to the findings of this study, Pou5f1 was the only known target 
of Nr5a2 in embryonic cells and hence this set the impetus to delve into the genome-
wide targets of Nr5a2 in mouse ESCs. From the ChIP-seq analysis, it is found that 
Nr5a2 shares several important common targets with its reprogramming counterparts 
of Sox2 and Klf4 (Figure 31D). Pou5f1 is one of the shared targets. However, Nr5a2 
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most likely works in a multifactorial fashion, and does not merely mediate 
reprogramming via the activation of one important gene. Notably, Nanog, the other 
important pluripotent gatekeeper
28
, besides Pou5f1, is also one of the downstream 
targets of Nr5a2 (Figure 31). Expression profiling of Nr5a2-deficient mouse ESCs 
also revealed that Nanog is a regulated gene of Nr5a2 (data not shown). More 
importantly, reprogramming assays reveal Nanog’s (Nanog does not enhance 
reprogramming with OSKM by itself) ability to rescue the knockdown effects of 
Nr5a2 during reprogramming, thus adding confidence to its important downstream 
position to Nr5a2.  
Tellingly, Hanna et al showed that Nanog can accelerate the kinetics of 
reprogramming in a mechanism independent of cell proliferation. Hence, the ability of 
Nr5a2 in accelerating the kinetics of reprogramming (Figure 11) may be explained in 
part through the mediation of its downstream target, Nanog. In addition, the 
overexpression of Nanog has been shown to be able to promote partially 
reprogrammed cells to a fully-reprogrammed state
28
. This capability of Nanog in 
reprogramming can thus in turn explain why Nr5a2 through Nanog, can mediate the 
enhancement in the generation of iPSCs. 
Therefore, Nr5a2 works in a relatively complex manner to mediate reprogramming 
namely through a variety of pluripotency-relevant genes such as Nanog as well as 
Pou5f1 to more efficiently derive iPSCs. It is noteworthy that besides these two 
notable targets of Nr5a2, there might be other targets of Nr5a2 that potentiate the 





4.5 Nr5a2 additionally reprograms mouse EpiSCs besides mouse somatic cells 
The Nr5a factors, Nr5a1 and Nr5a2, have not only been demonstrated in the 
reprogramming of mouse somatic cells such as MEFs
86
 (in the study herein) but also 
found to have a role in the reprogramming of early embryonic cells. Strikingly, both 
Nr5a2 and Nr5a1 were discovered to reprogram mouse EpiSCs to ESCs in a genome-
wide screen utilising the transposition of a piggyBac construct harbouring an 
activating enhancer and a promoter
187
. When this construct integrates into a 
favourable position of a particular gene locus (or regions neighbouring it), the 
transgenic enhancer and promoter will induce the expression of the gene in which it 
had been inserted. Using this technique to screen for reprogrammers of EpiSCs, Guo 
and Smith found that when the gene-activating piggyBac construct independently 
transposed into the Nr5a1 and Nr5a2 gene loci of EpiSCs, the induction of these 
genes were able to sustain the derived mouse ESC-like cells in LIF and 2i conditions 
(MEF and GSK3 chemical inhibitors). The authors also validated their findings by 
individually overexpressing Nr5a1 and Nr5a2 in EpiSCs and found that mouse iPSCs 
were indeed generated.   
Unlike mouse ESCs, mouse EpiSCs, although also pluripotent, possess an inactivated 
X-chromosome (in female cells), integrate poorly into the ICM after injection into a 
host blastocysts and are have a high propensity to differentiate into PGCs in vitro. 
Hence, as mouse EpiSCs are primed towards differentiation into PGC-like cells, they 
are appropriately labelled as “primed” pluripotent cells. In contrast to primed EpiSCs, 
mouse ESCs are described to be in a “naïve” state of pluripotency as they represent a 
developmentally-earlier and more malleable pluripotent cell type as compared to 
mouse EpiSCs
188
. Interestingly, Nr5a2 is not expressed in mouse EpiSCs unlike in 
mouse ESCs, in which it is moderately expressed
187
. Thus, it is likely that the 
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overexpression of an ESC-important factor within EpiSCs, which totally lacks that 
factor to begin with
187
, could account for such a reprogramming feat.  
Nonetheless, it is not surprising that the Nr5a factors are able to reprogram EpiSCs 
which are derived from the post-implantation stage embryo and hence their expected 
greater malleability to be converted (as compared to MEFs, which are typically 
derived from E13.5 mouse embryos, and can also be reprogrammed by Nr5a2) to 
iPSCs. Regardless, this discovery ultimately corroborates the reprogramming 
capabilities of the Nr5a factors in the reprogramming of mouse cells as shown by the 
study herein, albeit of different developmental time point. 
 
4.6 Species-specific actions of Nr5a2 in reprogramming 
As the canonical reprogramming code of Oct4, Sox2, Klf4 and c-Myc can be 
employed to generate both mouse and human iPSCs
48,49
, it is of course significant to 
investigate if Nr5a2 also exhibits reprogramming capabilities in human cells. 
However, what was demonstrated in murine reprogramming for Nr5a2 could not be 
recapitulated in human reprogramming (Figure 41). Not only was there no 
enhancement in the reprogramming of human fibroblasts, exogenous NR5A2 was also 
unable to replace exogenous OCT4 in the generation of human iPSCs (Figure 41).  
These results show that there is in fact some species-specific reprogramming factors, 
unlike what was previously thought as evidenced by the canonical reprogramming 
quartet. However, this result is not surprising as unlike mouse ESCs, human ESCs 
express very minimal levels of NR5A2
189
 and hence introducing NR5A2, a non-
highly expressed human ESC transcription factor may not necessarily promote the 
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reversion of human somatic cells to a human ESC state.  Notably, human ESCs, 
similar to mouse EpiSCs, are also regarded to be in a primed state of pluripotency as 
they share many defining traits including their flattened morphology as well as their 
growth factor requirements in culture.  Incidentally, as mentioned above, EpiSCs, 
which are murine equivalents to human ESCs also do not express Nr5a2
187
 and these 
Nr5a2-less EpiSCs must require the exogenous introduction of this transcription 
factor to create a mouse ESC-like state within themselves during reprogramming
187
. 
Interestingly, in an expression profiling study of nuclear receptors performed in both 
mouse and human ESCs, the authors claimed species-specific functions of Nr5a2, 
Esrrb and Dax1, nuclear receptors that were implicated in mouse ESC biology
189
. 
These nuclear receptors that are highly expressed in mouse ESCs have different 
expression patterns in human ESCs. Moreover, the authors also show that while 
Nr5a2 tends to be reduced upon differentiation in mouse ESCs, the opposite is true in 
human ESCs, in which its expression tends to increase upon differentiation
189
.  
Nonetheless, it is interesting to speculate that human ESCs might contain other 
Nr5a2-like factors (not necessarily Nr5a2) that orchestrate cognate mechanisms as 
shown in mouse ESCs. 
Taken together, it is interesting to report herein a nuclear receptor that might have a 
species-specific function, in which it enhances and replaces Oct4 in murine 
reprogramming but not do exhibit the same characteristics in the context of human 
reprogramming.  
 
 4.7 Mouse ESC-like human ESCs with Nr5a2 
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On this note, it is tempting to speculate if the overexpression of Nr5a2 might induce a 
mouse ESC-like state in human ESCs since this nuclear receptor can reprogram 
primed EpiSCs to an earlier pluripotent derivative
187
. Already, several groups have 
demonstrated the generation of mouse ESC-like human ESCs, which can be passaged 
as single cells, display shiny dome-shaped morphologies very akin to mouse ESCs 
that self-renew in culture conditions permissive for mouse ESCs
190-192
. These groups 
introduce various canonical reprogramming factors and/or a cocktail of chemical 
inhibitors in the presence of LIF to achieve such a reprogrammed state in human 
ESCs. However, it should be noted that Nr5a2 appears to display species-specific 
roles and what is observed in the murine system may not necessarily be similarly 
translated for the human system. In addition, Nr5a2 is also highly expressed in 
endodermal-derived organs and an elevation of Nr5a2 in human ESCs may induce 
them towards differentiation.  
Interestingly, a group showed that NR5A2 in combination with another nuclear 
receptor (RARγ), in addition with OSKM, are able to reprogram human somatic cells 
to iPSCs that resemble mouse ESCs with respect to their morphologies, gene 
expression as well as culture condition requirements
178
. These 6-factor-reprogrammed 
human cells were able to be grown in LIF in the presence of 2i. Notably, when the 
authors removed LIF and supplemented the culture media with FGF, the iPSCs 
assumed a hESC-like morphology instead.  
All in all, this study demonstrates that Nr5a2 is not only able to contribute to the 
reprogramming of mouse somatic cells and EpiSCs to a mouse ESC-like state but also 




4.8 Possible role of Nr5a2 in transdifferentiation 
The potency of Nr5a2 in mediating universal reprogramming of both mouse and 
human cells to a mouse ESC-like state is indeed remarkable
86,178,187
. Incidentally, 
Nr5a2 is not only expressed in mouse ESCs and the early developing embryo but also 
in endodermal-derived adult tissues such as the liver, pancreas and intestines
193-195
. 
Besides endodermal cells, Nr5a2 is also expressed in steroidogenic tissue such as the 
testes and ovaries
196
. Hence, Nr5a2 plays a dual role in establishing pluripotency as 
well as inducing myriad avenues of differentiation. In this respect, it is tempting to 
speculate the possibility of Nr5a2 in converting somatic cells such as fibroblasts into 
an endodermal or steroidogenic cell type.  It should be noted that even if it were able 
to cells into an endodermal derivative, there are many endodermal cell types in which 
Nr5a2 is expressed, and a heterogenous mixture of cells may eventually be derived. 
Nonetheless, specialised cell culture media with relevant supplements to solely derive 
one endodermal cell type can be utilised. Even if that is not possible, a multipotent 
endodermal precursor cell which Nr5a2 can create from its overexpression in 
fibroblast would be somewhat remarkable. Fortuitously, transdifferentiation of cells to 
endodermal or steroidogenic tissues have yet to be demonstrated and it would 










Altogether, a screen of nuclear receptors in their potential ability to augment the 
generation of mouse iPSCs reveals nuclear receptors Nr1i2 and Nr5a2 as enhancers of 
reprogramming. Besides being able to enhance the number of iPSC colonies 
generated, Nr5a2 is also able to enhance the kinetics of reprogramming. Strikingly, 
Nr5a2 can replace exogenous Oct4 in the reprogramming of MEFs. This finding is 
novel as no transcription factor, let alone factor have been previously shown to be 
able to substitute for exogenous Oct4 in the reprogramming process. Interestingly, 
besides commonly known to work through Oct4, Nr5a2 is herein shown to also work 
in part through Nanog to mediate the successful reprogramming of murine somatic 
cells. In summary, the nuclear receptor Nr5a2 is indeed a potent reprogramming 
factor that can partake in the reprogramming process to generate iPSCs, and more 
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